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In the current study, we examined the role of the Mitogen Activated Protein 
Kinases (MAPKs) on the biological responses of macrophages infected with Leishmania. 
The first section examined the role of MAPK/ERK in IL-10 production by Leishmania-
infected macrophages. The macrophage-derived IL-10 has been shown to exacerbate 
Leishmaniasis. However, the molecular mechanisms whereby Leishmaniasis prompts IL-
10 induction are poorly understood. A combination of two signals was necessary for IL-
10 induction by the Leishmania amastigotes-infected macrophages. The first signal is 
mediated by TLR ligation whereas the second signal is mediated by FcγR ligation, which 
yields a population of regulatory macrophages that produce high levels of IL-10. 
Infection of macrophages with L. amazonensis amastigotes from the lesion sites sparked 
MAPK/ERK activation, which was required, but not sufficient for IL-10 induction. In 
combination with an inflammatory stimulus, LMW-HA from the extracellular matrix, 
these parasites triggered the macrophages to highly produce IL-10. MAPK/ERK 
activation initiated an epigenetic modification of chromatin at the IL-10 locus, which 
allowed for transcription factor Sp1 binding to drive IL-10 transcription and subsequent 
production. U0126, an inhibitor of MAPK/ERK activation, decreased lesion progression 
in Leishmania infected mice.  
The second section examined the role of MAPK/p38 in cytokine production and 
vaccination against Leishmaniasis. TLR agonists activate macrophages to produce pro-
inflammatory cytokines and reactive oxygen intermediates. Inhibition of MAPK/p38 
reciprocally increased IL-12 but decreased TNFα production from LPS-stimulated 
macrophages, which also occurred following stimulation by a variety of other TLR 
agonists, and using different APCs. MAPK/p38 inhibition induced IL-12p40 mRNA 
accumulation mainly due to enhanced mRNA stability, which was independent of IL-10. 
Similar results were observed by knocking down MAPK/p38 using specific siRNAs or by 
targeted deletion of MKK3. IL-12 production following the inhibition of MAPK/p38 
skewed antigen-specific T cells to produce more IFN-γ and less IL-4 in vitro. A 
MAPK/p38 inhibitor was applied as an adjuvant to vaccine mice against L. major, which 
resulted in smaller lesions with fewer parasites. 
Our findings reveal an important role of MAPKs in the Leishmania pathogenesis, 
and suggest that the manipulation of these kinases may provide novel therapeutics for 
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CHAPTER 1: INTRODUCTION 
Part 1: Leishmania Infection and Host Defense 
I. Leishmania 
            Leishmaniasis is an infectious disease with worldwide prevalence. The World 
Health Organization (WHO) estimates that about 12 million symptomatic and 
asymptomatic humans are infected by Leishmania in 88 countries. Most of the affected 
countries are in the tropics or subtropics. Leishmaniasis is found in the areas of America -
from Mexico to northern Argentina (not in Uruguay, Chile, or Canada), southern Europe, 
Asia (not in southeast part of Asia), the Middle East, and Africa (particularly E st and 
North Africa). More than 90 percent of visceral leishmaniasis (VL) cases are found in 
India, Bangladesh, Nepal, Sudan, and Brazil.  
Leishmania Life Cycle 
            Leishmania exists in two developmental forms: promastigote and amastigote. 
When a sandfly takes a blood meal from an infected patient, parasites are released from 
infected macrophages and differentiate from intracellular amastigotes to extracellular 
procyclic promastigotes that resides in the digestive tract of the sandfly (Sacks et al., 
1993). Then in the sandfly’s gut the immature procyclic promastigote undergoes a 
transformation to a form that is infectious to mammalian macrophages, called the 
metacyclic promastigote. This form is morphologically distinct from non-infective form, 
with an elongated, narrow body with a long flagellum more than twice the body size. The 





Figure 1. Leishmania life cycle. (1) Leishmania infected, female sandfly takes a blood meal and 
transfers metacyclic promastigotes to mammalian host. (2) Macrophage takes up promastigote. (3) 
Promastigote is exposed to macrophage phagolysosome. (4) Promastigote transforms to 
amastigote form permitting survival in phagolysosome. (5) Amastigote replicates. (6) Amastigote 
replication leads to macrophage lysis. (7) Uninfected sandfly takes a blood meal and ingests 
amastigotes. (8) In the sandfly gut, each amastigote differentiates into promastigote form 
preparing for eventual transfer. Adapted from the Centers for Disease Control, www.cdc.gov. 
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composed of molecules attached by glycosylphosphatidylinositol (GPI) anchors. T e 
most abundant constituent is lipophosphoglycan (LPG). Procyclic promastigotes exprs 
shorter LPG and metacyclic promastigotes express longer LPG (Awasthi et al., 2004). 
When an infected sandfly takes a blood meal, these promastigotes are injected ito he
mammalian host. The infective metacyclic promastigotes are taken up by phagocytic cells 
to rapidly transform into the amastigote form, which is non-motile and oval-shaped. 
Amastigotes live and replicate in the phagolysosomes of mononuclear phagocytes. The 
infection spreads when infected mononuclear phagocytes burst to release amastigotes into 
the surrounding tissue where they enter neighboring macrophages. 
Leishmania are intracellular parasites that reside primarily within host tissue 
macrophages. Although polymorphonuclear neutrophil granulocytes (PMN) are able to 
internalize leishmania promastigotes, these cells are not considered to be host cells for 
the parasites due to their short life span. Leishmania does not enter dendritic cells (DCs) 
as efficiently as macrophages (Henri et al., 2002), possibly due to the fact that 
macrophages express higher levels of surface receptors that mediate phagocytosis than 
the splenic DCs.  
Disease Manifestation  
            There are three main clinical categories of Leishmaniasis: cutaneous (L. major, L. 
amazoneisis, L. mexicana and L. tropica), mucocutaneous (L. braziliensis and L. 
guyanensis) and visceral (L. donovani, L. chagasi, and L. infantum). According to the 
U.S. Centers for Disease Control and Prevention, every year there is an estimated 
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incidence of 1.5 million cases of cutaneous leishmaniasis (CL) and 500,000 cases of 
visceral leishmaniasis (VL) (www.cdc.gov/ncidod/dpd/parasites/leishmania/default.htm). 
            CL patients develop small skin lesions after being bitten by sand flies. The lesions 
will eventually heal with scarring. Mucocutaneous leishmaniasis (MCL) commences with 
skin ulcers, but eventually leads to extensive and disfiguring destruction of mucus 
membranes of the nose, mouth and throat. VL (also known as kala-azar) is the most 
severe form and potentially fatal if untreated. Many patients do not have symptoms for a 
few months after infection. Later they can manifest symptoms of fever, weight loss, 
damage to the spleen and liver, and anaemia.  
Diagnosis, Treatment and Vaccination 
            The best way to identify a cutaneous infection is to take a biopsy from the edge of 
the lesion and analyze it microscopically for the presence of parasites.  Altrnatively 
parasites from the biopsy can be grown in culture. In addition, PCR-based methods that 
amplify mitochondrial (kinetoplast) DNA common to all Leishmania species can be used 
to accurately diagnose leishmaniasis. For visceral patients, blood antibodies levels can be 
used as diagnostic markers (Murray et al., 2005). 
            Cutaneous leishmaniasis can usually heal without any treatment. For visceral 
leishmaniasis, several drugs have been used in clinics. The most commonly used drug is 
antimony (pentavalent antimonials). Two other drugs that are more expensive include 
amphotericin B and pentamidine. Miltefosin, a newly developed drug for both visceral 
and cutaneous leishmaniasis, is more affordable. Al  the treatments have side effects 
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including nausea, pain, vomiting, anorexia, myalgia, arthralgia, headache and malaise. 
Unfortunately, in some patients, the parasites start to become resistant to antimony. 
Because of side effects and drug resistance, it is becoming urgent to develop a leishmania 
vaccine. There is no effective vaccine currently available (Schwartz et al., 2006).  
 
            Since Leishmania is intracellular parasite, the development of vaccines is mainly 
focused on the generation of T helper cells (Th1) immunity. Some Leishmania vaccine 
studies have shown that immunization with defined parasite antigens in combination with 
Th1-inducing adjuvants provides protection against several L ishmania species in various 
strains of inbred mice. Although the generation of a vaccine-induced Th1 response is 
necessary for protection, it may not be sufficient. Control of deactivating responses 
during infection has been proposed to improve vaccine success (Wilson et al., 2005). 
Thus understanding of how host responds to Leishmania is helpful to design effective 
vaccines.  
II. Host Defense against Leishmania 
Host Defense Overview 
            The host immune system is composed of innate and adaptive immunity. Innate 
immunity provides the first lines of defense against microbes and other pathogens.  This 
is mediated primarily by neutrophils, macrophages, DCs and natural killer cells (NK 
cells). Adaptive immune responses develop later, and are mediated by T and B 
lymphocytes as well as their products. Antigen-specific lymphocytes become activated 
and proliferate upon recognizing antigens. B cells produce antibodies to neutralize and 
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eliminate extracellular microbes. CD4+ T and CD8+ T cells are two major groups of T 
cells. Under the influence of cytokines produced from innate immune cells, naïve CD4+ 
Th cells differentiate into Th1, Th2, Th17, or regulatory T cells (Treg). In the simplified 
terms, Th1 cells produce interferon-γ (IFN-γ) to promote cell-mediated immunity 
whereas Th2 cells are associated with humoral immunity by producing IL-4 to promote 
class-switching of immunoglobulin genes in B cells. CD8+ T cells can contribute to Th1 
responses by producing IFN-γ, and they can destroy the cells infected with intracellular 
microorganisms including viruses and some bacteria. Mammalian host protection against
Leishmania infection is mainly dependent on the development of IFN-γ producing CD4+ 
Th1 and CD8+ T cells, which trigger enhanced leishmanicidal activity by macrophages. 
In Leishmania infected mouse models, susceptible BALB/c mice are unable to control 
infection because of an aberrant Th2 response, while resistant C57BL/6 mice control 
infections by developing protective Th1 responses (Scott et al., 1989; Wakil et al., 1998; 
Fowell et al., 1998; Scharton-Kersten and Scott, 1995).  
T cell Responses 
            T cell-mediated immunity has a dominant role in human and experimental 
leishmaniasis. During Leishmania infection, specific Th cells are generated to establish 
an immune response that is essential to determine the outcome of the infection. Th cells
develop into two major subtypes, Th1 and Th2, which mainly depend on the nature of 
priming during differentiation.  IL-4 induces Th2 cells, whereas IL-12 induces Th1 
differentiation. Th1 and Th2 cells can be distinguished by the cytokines that they secr te. 
Th1 cells secrete IFN-γ to activate cell-mediated immunity, whereas Th2 cells secrete 
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cytokines such as IL-4 that promote antibody responses. The Th1/Th2 paradigm of 
resistance/susceptibility to Leishmania mainly relates to murine infections using L. 
major. Most strains of mice (C57BL/6, C3H, and CBA) develop a self-limiting cutaneous 
disease when they are inoculated with L. major. In these mice, the infection is resolved 
via Th1 cells-mediated immunity characterized by the production of IFN-γ. IFN-γ 
induces the production of nitric oxide (NO) from infected macrophages to destroy the 
intracellular parasite. BALB/c mice are extremely sensitive to L. major infection. The 
resulting immune response is characterized by an expansion of Th2 cells and the 
production of IL-4, a hallmark of Th2 immunity. It has been proposed that antibody has 
no protective role for infection initiated by Leishmania (Kima et al., 2000; Miles et al., 
2005). Previous studies suggested that antibody generated during leishmaniasis could 
contribute to disease progression by their activation of Fcγ receptors on the macrophages 
to produce a large amount of IL-10 (Miles t al., 2005). IL-10 has been known to render 
macrophages refractory to IFN-γ activation for intracellular killing of Leishmania. 
BALB/c IL-10-deficient mice are relatively resistant to L. major infection (Kane and 
Mosser, 2001), although this resistance is significantly improved when both IL-4 receptor 
and IL-10 are deleted (Noben-Trauth e  al., 2003). The role of Th17 cells in the 
development of leishmaniasis has recently been assessed (Lopez et al., 2009). It has been 
found that L. major infected BALB/c mice produced increased levels of IL-17 and IL-17-
deficient BALB/c mice exhibited attenuated disease progress despite of typical Th2 
phenotype. The role of T cells in leishmaniasis is more complicated than what we 
thought, and some are beneficial whereas others are detrimental.  
Cytokines IL-12 and IL-10 
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            During Leishmania infection, the cells of the innate and adaptive immune 
response will secrete a variety of cytokines, including IL-1, IL-4, IL-6, IL-10, IL-12, IL-
13, IL-23, IFN-γ, and tumor necrosis factor-α (TNF-α). IL-12 and IL-10 are two 
important cytokines with opposite functions in maintaining immune homeostasis. IL-12 
primarily drives the pro-inflammatory cell-mediated immune response whereas IL-10 
mainly antagonizes inflammation.  
            IL-12 is produced by activated antigen presenting cells (APCs) such as DCsnd 
macrophages (Trinchieri, 2003). IL-12p70 is a heterodimeric cytokine composed of two 
subunits, p35 and p40. They are encoded by two separate genes, and their expression is 
independently regulated at the transcriptional and posttranscriptional levels. IL-12p70 
uses IL-12 receptor (IL-12R) β1 (p40) and IL-12R β2 (p35) chain for signaling. Once 
activated by the binding of IL-12p70, signal transduction through IL-12R induces 
tyrosine phosphorylation of the Janus tyrosine kinases Jak2 and Tyk2 that are 
respectively associated with IL-12Rβ1 and IL-12Rβ2. Activated Jak2/Tyk2 causes the 
phosphorylation of the cytoplasmic tails of the receptors and the recruitment of a number 
of the signal transducer and activator of transcription (STATs), primarily STAT4 that 
drives most of the effects of IL-12. STAT4 homodimers translocate into the nucleus and 
binds to STAT elements to induce the production of the immune response genes. IL-23, 
another heterodimeric cytokine from IL-12 family, has similar biological function as IL-
12p70. IL-23 is composed of p19 and p40. IL-23 receptor (IL-23R) consists of the IL-
12Rβ1 and the IL-23R chain.  
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            Both of IL-12p70 and IL-23 can drive Th1 responses during T-cell activation and 
IFN-γ induction (Hunter, 2005). While IL-23 acts on memory CD4+T cells, IL-12p70 
preferentially acts on naïve CD4+T cells. IL-12/23-induced IFN-γ in turn activates 
macrophages to exert enhanced microbial killing ability by forming a proinflammatory 
loop to increase other proinflammatory cytokine production. Recently, IL-23 is found as 
a potent inducer for IL-17 but not IFN-γ in murine T cells (Stumhofer et al., 2007). IL-17 
has been suggested as a cytokine to promote leishmaniasis (Lopez et al., 2009). Thus, in 
contrast to IL-12p70, IL-23 is implicated in disease progression rather than eradication 
(Lopez et al., 2009). IL-12p40 can exist in a monomeric or homodimeric forms. 
Monomeric p40 is induced in excess of several to 1000-fold over the other heterodimers 
subunits, p35 of IL-12p70 and p19 of IL-23. Redundant p40 subunits can form p80 
homodimers that may work as antagonists of IL-12p70 and IL-23 in murine models 
because they competitively bind to the IL-12Rβ1 (Cooper and Khader, 2007). The proper 
balance between these IL-12p40-containing cytokines can control the development of 
normal or pathological Th1 immune responses. IL-12p40-/- mice lack of both IL-12p70 
and IL-23 show deficient Th1 development, reduced DTH responses, and NK cell 
responses (Trinchieri, 2003). However IL-12p35-/- mice only have some phenotypes of 
IL-12p40-/- mice, but not all (Hunter, 2005).  
            Effective primary immunity against L. major requires IL-12-dependent 
production of IFN-γ from CD4+ T cells (Sypek et al., 1993; Scharton-Kersten et al., 
1995). IL-12 by APCs and IFN-γ by T cells play important roles in the intracellular 
killing of the parasites. IL-12p40-/- mice were more susceptible to L. amazoneisis than the 
wild type C57BL/6 (Hernández et al., 2006) At the time of infection, treatment with 
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recombinant IL-12 or with antibodies to IL-4, CD4, or TGF-ß has been shown to shift the 
immune response to Th1 profile and enable BALB/c mice to resolve L. major or L. 
amazoneisis infection. (Barral-Netto et al., 1992; Chatelain et al., 1992; Hilkens et al., 
1996;  Sadick et al., 1990). 
            IL-10 can be produced as a non-covalent homodimer with an apparent molecular 
weight of 37 kDa (Moore t al., 2001; Mosser and Zhang, 2008). This anti-inflammatory 
cytokine is produced from Th cells, Treg cells, macrophages, B cells and non-immune 
cells including keratinocytes, epithelial cells, and tumor cells. IL-10 receptor (IL-10R) 
composes of two subunits. IL-10 binds to IL-10R1 to trigger its association with IL-10R2 
and subsequent activation of Jak1 and Tyk2 that are associated with IL-10R1 and IL-
10R2 respectively. Activated Jak1 and Tyk2 induce phosphorylation of STAT3. 
Phosphorylated STAT3 forms homodimers that translocate into the nucleus and bind to 
corresponding cis-elements to regulate expression of the immune response genes, such as 
IL-10 itself and suppressor of cytokine signaling 3 (SOCS3) that controls the quality and 
quantity of STAT activation.  
            IL-10Rs are expressed on most cells so that a large number of diverse cells ar
able to respond to IL-10 (Mosser and Zhang, 2008). IL-10 exerts most of its biological 
function through its interactions with macrophages and DCs. IL-10 can reduce antigen 
presentation by down-regulation of major histocompatibility complex class-II (MHC 
class-II) and the co-stimulatory molecules, CD80, CD86, B7.1 and B7.2, which are 
required for the activation of naïve T-cells (Grütz, 2005).  The other profound function of 
IL-10 is to inhibit the production of type-1 cytokines such as IL-1, IL-6, IL-12, INF-γ, 
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TNF-α and to block their actions (Donnelly et al., 2004). IL-10 has been shown to rescue 
BALB/c mice from LPS induced endotoxemia (Howard et al., 1993; Anderson and 
Mosser, 2002a). Being an anti-inflammatory cytokine, IL-10 is critical to maintain a 
balance between protecting the host from pathogen assaults and minimizing the damag s 
caused by excessive inflammation (Reed t al., 1994; Wagner et al., 1994). IL-10-/- mice 
appear to be normal at birth with normal numbers and distribution of T cell, B cells and 
macrophages. However, IL-10-/- mice can develop spontaneous enterocolitis after 4–6 
weeks with the appearance of adenocarcinomas at advanced stages, especially wh n not 
housed under specific pathogen-free conditions (Kuhn et al., 1993).  Administration of 
IL-10 from birth or treatment with anti-IFN-γ or anti-IL-12 monoclonal antibody can 
prevent enterocolitis in IL-10-/- mice (Davidson et al., 1998). Of note, IL-10 treatment 
could only ameliorate established disease without successful cure. CD4+ T cells isolated 
from diseased colon were found to produce high levels of IFN-γ and TNFα. Transfer of 
these cells could induce the host mice to develop the disease, indicating that the 
unbalanced interaction between enteric flora and inflammatory cells in the absence of IL-
10 results in uncontrolled Th1 responses. Besides its inhibitory features, IL-10 shows 
stimulatory activities by co-stimulating B cells and contributes to immunoglobulin (Ig) 
class switching (Go et al., 1990). IL-10 can enhance the expression of Fc gamma receptor 
(FcγR) on macrophages (Calzada-Wack et al., 1996), which are correlated with enhanced 
phagocytosis of opsonized particles (Capsoni et al., 1995) and potential pathogens. 
            IL-10 is important in regulating immune responses to intracellular Leishmania by 
inhibiting the production of a type 1 immune response and preventing macrophages from 
activation to kill the parasites. Host macrophages can also produce high amounts of IL-
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10. IL-10 inhibited the activation of macrophages exposed to IFN-γ/ lipopolysaccharide 
(LPS) by producing less TNF-α and almost no IL-12 (Kane and Mosser, 2000). Thus, 
Leishmania parasites undergo replication within host macrophages, which eventually 
leads to pathology (Kane and Mosser, 2001). IL-10-/- BALB/c mice are relatively 
resistant to infection. These infected mice have reduced footpad swelling and fewer 
parasites in the lesions relative to wild type mice (Kane and Mosser, 2001; Buxbaum and 
Scott, 2005). Increase of IL-10 in the infected mice, either by the administration of 
exogenous IL-10 (Lang et al., 2002) or the induction of endogenous IL-10 (Miles et al., 
2005) can exacerbate disease progression. In murine models of visceral (Murray et al., 
2003) and cutaneous (Chatelain et al., 1999; Kane and Mosser, 2001) leishmaniasis, IL-
10 contributes to disease progression. In humans, IL-10 levels were shown to directly 
correlate with disease severity and high levels of plasma IL-10 were found to be 
predictive of the development of post-kala-azar dermal leishmaniasis (Karp et al., 1993). 
However the immune deviation is not a true predictor of disease progression in humans. 
For example, although ample IFN-γ is produced during L. donovani caused visceral 
leishmaniasis, infected hosts generally fail to control the disease (Kane and Mosser, 
2001). 
Part 2: The Role of Macrophages in Leishmania Infection  
I. Macrophage Heterogeneity 
            In response to macrophage colony-stimulating factor (M-CSF) or granulocyte/ 
macrophage colony-stimulating factor (GM-CSF), a monocyte lineage of haematopoietic 
stem cells that are also the same stem cells of neutrophils, eosinophils, basophils and 
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mast cells generated from bone marrow undergo differentiation into monoblasts, pro-
monocytes and monocytes. The differentiated mononuclear cells exit the bone marrow to 
enter the bloodstream. Macrophages and DCs are differentiated from those circulating 
peripheral blood mononuclear cells (PBMC). From the blood, they migrate into different 
tissues as resident cells or in response of inflammation as inflammatory cells (Zhang and 
Mosser, 2009). 
          Macrophages are phagocytic cells that are involved in the removal of apoptotic 
cells and cellular debris. This clearance is independent of other immune cell signa ing 
and results in the releasing of little or no immune mediators (Kono and Rock, 2008). This 
daily activity is mediated by scavenger receptors, complement receptors, in e grins, 
phosphatidyl serine receptors and thrombospondin receptors (Erwig and Henson, 2007).  
           Macrophages are important immune effector cells that participate in both the 
innate and adaptive immune responses to eliminate pathogens. In response to 
environment cues, macrophages change their phenotype and physiology including 
alterations in the surface proteins expression and the cytokines production. Therefore, 
macrophages are heterogeneous cells not only with respect to biochemical marker 
expression but also with respect to different physiological functions.  Macrophages are 
strongly influenced by the tissue microenvironment. Our laboratory had developed a 
classification of macrophage phenotypes based on the three major macrophage functions: 
host defense, wound healing and immune regulation (Mosser and Edwards, 2008).  The 
activated macrophages corresponding to these three activities are: classically activated 





Figure 2. The classification of activated macrophages. Resting macrophages can respond to 
different signals and give rise to three populations. Each of these three populations has a distinct 
physiology. In response to IFNγ and TLR4, classically activated macrophages arise to produce 
high amount of IL-12 and NO. They have microbicidal activity. Wound-healing macrophages 
arise in response to IL-4/IL-13 and they increase RELMα, YM expression. They have a role in 
tissue repair. Regulatory macrophages are generated in response to LPS induced TLR4 and 




Classically Activated Macrophages  
            Classically activated macrophages are generated in response to stimulation with 
IFN-γ plus any TNFα inducer, which includes all TLR ligands (Mosser and Zhang, 
2009). NK cells are important early source of innate IFN-γ production. Th1 cells and 
CD8+ T cells are a more stable source of IFN-γ during adaptive immune responses. In 
some settings, IFN-β can replace IFN-γ to activate classically activated macrophages. 
The role of classically activated macrophages in host defense has been well studied. 
Upon activation, they become effective APCs due to highly induced expression of 
surface molecules, such as MHC class-II and B7. These activated macrophages increase 
the production of superoxide anions, and nitrogen radicals, which increase their killing 
ability (Dale et al., 2008). Macrophages activated with IFN-γ were shown to be able to 
restrict the parasites intracellular growth. Most importantly, these macrophages produce 
large amounts of pro-inflammatory cytokines, IL-12 and IL-23 for Th1 differentiation. 
However, the excessive and uncontrolled inflammation by classically activated 
macrophages can lead to host–tissue damage, such as tissue destruction, chronic 
granuloma formation and autoimmune diseases, including inflammatory bowel disease 
and rheumatoid arthritis (Langrish et al., 2005; Szekanecz and Koch, 2007). 
 Wound-healing Macrophages 
            In contrast to the role of Th1 cells-produced IFN-γ on macrophages, Th2 cells-
produced IL-4 and/or IL-13 act on macrophages to up-regulate mannose receptor that was 
classified as a distinctive marker of IL-4-activated macrophages together wi  the 
induction of MHC class II antigens, and those macrophages have been termed as 
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alternative activated macrophages (Stein et al., 1992) or wound-healing macrophages 
(Mosser and Edwards, 2008). In the innate immunity, granulocytes, such as basophils and 
mast cells, are the important early sources of IL-4. Th2 cells are major source of IL-4 and 
IL-13 in adaptive immune responses (Paul, 1991). These wound-healing macrophages 
increase arginase activity to convert arginine to ornithine that is a precursor of 
polyamines and collagen for extracellular matrix, thereby contributing to the tissue repair. 
These cells exhibit high expressions of mannose receptors, chitinase and chitinase-like 
molecules such as YM1, YM2 and resistin-like molecule-α (RELMα). Although 
expression of MHC class-II molecules can be found to some extent, these cells are not 
efficient for antigen presentation, and they may even inhibit T cell proliferation (Edwards 
et al., 2006). These macrophages produce much less pro-inflammatory cytokines, toxic 
oxygen and nitrogen radicals and are ineffective at killing intracellular microbes (Munder 
et al., 1998; Gordon, 2003). This population of macrophages is more susceptible to some 
intracellular infections. For example, IL-4 induced polyamine production can contribute 
to the intracellular growth of Leishmania major in macrophages (Kropf et al., 2005.). The 
uncontrolled activation of wound-healing macrophages can also lead to host tissue 
damage due to dysregulated fibrosis.  This pathology has been observed in helminthic 
infections, such as chronic schistosomiasis (Hesse t al., 2001).  
Regulatory Macrophages 
            Regulatory macrophages are generated by stimulation of cells in the presence of a 
TLR ligand along with a second stimulus, including immune complexes, prostaglandins, 
G-protein-coupled receptor (GPCR) ligands, IL-10 and perhaps the phagocytosis of 
apoptotic cells (Mosser and Edwards, 2008). Our lab first discovered and characterized a 
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subpopulation of regulatory macrophages in vitro following their activation by two 
signals: LPS plus immune complexes (Mosser DM, 2003). The primary stimulus signals 
through one of the TLRs, whereas the second stimulus signals through the FcγRs. The 
second signal is accomplished by the binding of many different IgG-opsonized antigens 
(Anderson and Mosser, 2002a; Anderson and Mosser, 2002b). These regulatory 
macrophages produce high amounts of anti-inflammatory cytokine IL-10, and diminished 
production of the pro-inflammatory cytokine IL-12. The ratio of IL-10 to IL-12 can 
define regulatory macrophages. The high IL-10 production is dependent on the activation 
of the mitogen-activated protein kinase (MAPK)-extracellular signal-regulated kinase 
(ERK) signaling pathway (Lucas et al., 2005). Regulatory macrophages can resolve 
inflammation because IL-10 can inhibit various pro-inflammatory cytokines productin 
and activity. We hypothesize that minimizing the population of regulatory macrophages 
during a vaccination may be helpful for vaccine development where the induction of pro-
inflammatory cytokines is required for immunity. Similar to classically ctivated 
macrophages, regulatory macrophages are effective APCs with the high expression of 
MHC class-II and co-stimulatory molecules CD80, CD86 and B7 (Edwards et al., 2006).  
Previous work from this laboratory has shown that in chronic leishmaniasis, amastigotes 
bind host IgG to form immune complexes (Kane and Mosser, 2001; Miles et al, 2005).  
These amastigotes bind to FcγR on macrophages and induce IL-10 production.  The high 
levels of IL-10 by these macrophages can render nearby cells refractory to he activating 
effects of IFN-γ preventing them from making reactive nitrogen species and killing 
intracellular Leishmania spp. (Kane and Mosser, 2001). 
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Both classically activated macrophages and regulatory macrophages can function 
as APCs to influence Th cell differentiation (Anderson and Mosser, 2002a). Classically 
activated macrophages stimulate T cells to primarily produce IFN-γ in response to 
antigen, whereas regulatory macrophages induce T cells to produce high levels of IL-4, 
which in turn induce B cells to produce antibody to that antigen. IL-12 secretion by 
classically activated macrophages induced IFN-γ production by T cells, whereas IL-10 
secretion by regulatory macrophages results in IL-4 production by T cells. 
            In summary, macrophages exhibit remarkable plasticity in response to both innate 
and adaptive signals. They are functionally specialized to promote distinct physiology in 
host defense, wound-healing and immune regulation. Each macrophage population has 
the potential to be dangerous if not appropriately regulated. By manipulating different 
population of macrophages, we can develop therapeutic strategies to control various 
diseases and design better vaccines.    
II. Receptors 
            The host is equipped with a number of pattern recognition receptors (PRRs) that 
are expressed on the immune cells. These receptors recognize molecules with highly 
conserved pathogen associated molecular patterns (PAMPs) (Janeway and Medzhitov, 
2002). PAMPs are mainly identified as essential microbial components with dist nct 
features that are not associated with host molecules. Depending on the recognition f 
microbes and resultant activation of intracellular signaling pathways, the innate immune 
system triggers and controls the major aspects of the adaptive immune response. 
Macrophages express various PRRs, including Toll-like receptors (TLRs), scavenger 
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receptors, complement receptors, C-type lectin receptors and NOD-like receptors (Zhang 
and Mosser, 2008). TLRs are the most well-characterized among these receptors.   
Toll-like Receptors 
            TLRs play an important role both in innate immunity and in the development of 
adaptive immune responses (Janeway and Medzhitov, 2002; Akira and Takeda, 2004). 
TLRs have broad specificity for conserved molecular patterns shared by bacteria, viruses 
and parasites. TLR activation leads to signal transduction cascades for cells to trigger the 
production of inflammatory cytokines and the induction of antimicrobial genes. They also 
induce the up-regulation of co-stimulatory molecules for the adaptive immune response.  
            Some 13 TLRs in mice and 11 TLRs in humans have been identified to date 
(Akira and Takeda, 2004) (Table 1). TLRs have an extracellular region consisting of a 
leucine-rich repeat (LRR) motif, and a cytoplasmic tail of a Toll/IL-1 receptor (TIR) 
domain. The TIR domain is conserved in all TLRs except TLR3 and this domain binds to 
adaptor proteins to mediate TLR signaling pathways. These activating adaptors include 
myeloid differentiation primary response gene 88 (MyD88), MyD88-adaptor-like 
(MAL)/TIR domain-containing adaptor protein (TIRAP), TIR domain-containing adaptor 
inducing IFN-β (TRIF)/TIR domain-containing adaptor molecule-1 (TICAM-1) and 
TRIF-related adaptor molecule (TRAM). MyD88 is the key adaptor protein in almost all 
the TLRs signaling except TLR3. TLR3 mediates through TRIF/TICAM-1 adaptors. LPS 
induced TLR4 signaling can be transmitted through MyD88-dependent and -independent 





Locations Receptors Ligands Adapters 
Cell surface TLR1 Triacyl lipoprotein (bacteria and 
mycobacteria) 
MyD88/MAL 
Cell surface TLR2 Peptidoglycan (Gram-positive bacteria); 
lipoarabinomannan (Mycobacteria), 
hemagglutinin (Measles virus), 
phospholipomannan (Candida), 
glycosylphosphophatidyl inositol mucin 
(Trypanosoma); lipoproteins; lipoteichoic 
acid; porins(Neisseria); fungi zymosan    
MyD88/MAL 
Cell compartment TLR3 Virus double-standed RNA;poly I:C TRIF 
Cell surface TLR4 LPS (Gram-negative bacteria); vial 
glycoproteins; mannan (Candida); hyaluronic 
acid; gp96; heparin sulfate; heat shock 
proteins; surficant protein-A; 
glycoinositolphospholipids; fibrinogens; β-
defensin 2; HMGB1  
MyD88/MAL 
TRIF/TRAM 
Cell surface TLR5 Flagellin MyD88 




Cell compartment TLR7 Virus single-standed RNA; bropi imine, 
imidazoquinoline and loxoribine (small 
synthetic compounds) 
MyD88 
Cell compartment TLR8 Virus single-standed RNA  MyD88 
Cell compartment TLR9 CpG DNA(bacteria and vial); dsDNA viruses; 
hemozoin (Plasmodium) 
MyD88 
Cell surface TLR10 Unknown (only in human) Unknown 
Cell surface TLR11 profilin-like protein(Toxoplasma gondi); 
uropathogenic bacteria 
MyD88 
Unknown TLR12 Unknown (only in mice) Unknown 
Unknown TLR13 Unknown (only in mice) Unknown 





Figure 3: TLR4 mediated signaling pathways. LPS binds to the LPS coreceptors CD14 and 
MD2 to trigger TLR4 activation. Activation of TLR4 initiates MyD88-dependant and MyD88-
independent (TRIF-dependent) signaling pathways and results in the activation of NF-κB, 





            The FcγRs are expressed on numerous cells of hematopoietic origin. FcγRs play 
critical roles in phagocytosis, clearance of immune complexes, cytokine production and 
the respiratory burst (Unkeless et al., 1988). The FcγR is composed of an α chain that 
binds the Fc portion of IgG, and γ chains that are associated with one or more signal 
transduction regions (Nimmerjahn and Ravetch. 2008). The γ c ain is a 7 kD polypeptide 
and is homologous to the T cell receptor’s ζ chain. Four different classes of FcγRs are 
identified in mice with slightly different biological functions (Figure 4). Macrophages 
express all the four forms of FcγR on their surfaces. The FcγRI (CD64), FcγRIII (CD16) 
and FcγRIV, consist of a α chain, and a γ signaling chain that contains the immuno-
receptor tyrosine-based activation motif (ITAM). Signaling mediated by γ chain is 
required for the induction of IL-10 following FcγR ligation on macrophages (Capsoni et 
al., 1995; Sutterwala et al., 1998). Mice express only the FcγRIIb, a receptor that 
contains a α chain with an immuno-receptor tyrosine-based inhibition motif (ITIM) in its 
cytoplasmic region, while humans have two FcγRII: FcγRIIa and FcγRIIb. FcγRIIa has an 
ITAM containing α chain whereas FcγRIIb has an ITIM containing α chain.  
            FcγRI is the high affinity receptor specific for monomeric IgG. In human cells, 
this receptor binds IgG1 and IgG3 tightly, while in the mouse, the preferred monomeric 
IgG is IgG2a. Both FcγRII and FcγRIII are low affinity receptors that bind poorly to 
monomeric IgG, but can bind IgG coated antigens. FcγRIV is a newly identified receptor 









monomers or immune complex less effectively than FcγRI but stronger than both FcγRII 
and FcγRIII (Nimmerjahn et al., 2005).  
            Antibodies specific to Leishmania are prominent in human visceral leishmaniasis 
and they are also produced in BALB/c mice during infection (Junqueira et al., 2003; 
Ghosh et al., 1995; Casato et al., 1999; Jeronimo et al., 2000; Galvão-Castro et al., 1984; 
Elassad et al., 1994). In humans and mice, the levels of IgG increase as disease 
progresses and parasites disseminate (Iniesta et al., 2008). Instead of providing 
protection, IgG antibodies to Leishmania actually made L. major infections worse in 
BALB/c mice (Miles et al., 2005).  Mice lacking B cells actually had smaller lesions with 
fewer parasites (Smelt e al., 2000).  The increase in disease severity is mainly due to an 
increase in IL-10 production. It has been shown that Leishmania amastigotes derived 
from infected footpads have host-derived IgG on their surface (Pearson and Roberts, 
1990; Kane and Mosser, 2001). In the presence of TLR ligand, the interaction of FcγR 
with opsonized parasites shuts off the production of IL-12 and induces the production of 
IL-10 from macrophages. This reversal in cytokine production blocks the Th1 
inflammatory response and biases toward a Th2 anti-inflammatory response. 
            Cross-linking of FcγRs on macrophages with IgG-opsonized particles triggers a 
downstream signaling cascade (Nimmerjahn and Ravetch, 2008). Previous studies 
suggested that phosphorylation of two ITAM tyrosines of the FcγRs by tyrosine kinases 
of Src-family leads to recruitment and activation of the spleen tyrosine kinase (Syk). 
ITAMs consist of evolutionarily conserved amino-acid sequence motifs of 
D/ExYxxLx(6-8)YxxL. Syk belongs to the Syk/ZAP-70 family of non-receptor kinases 
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and is characterized by two N-terminal Src homology 2 (SH2) domains and a C-terminal 
kinase domain with a flexible linker between them. Syk is activated through: (1) binding 
of its SH2 domains to phosphorylated ITAMs in the cytoplasmic tails of Ig-α and -β, (2) 
phosphorylation by Src family kinases, and (3) auto-phosphrylation (Wossning et al., 
2006). Syk plays a key role in immuno-receptor-mediated phagocytosis (Shi et al., 2006). 
            Syk can activate phospholipase C (PLC)-γ1, phophatidylinositol 1-kinase (PI 3-
kinase), and regulators of Ras and other Ras-like G proteins such as Shc and Vav. Syk 
can be associated with FcγRIIa and the tyrosine phosphorylated γ chain of FcγRI and 
FcγRIII (Crowley et al., 1997). Syk is required for FcγR-induced phagocytosis of 
opsonized particles, but not for the phagocytosis of latex beads or unopsonized 
microorganisms. Syk is important for many FcγR-induced signaling events, but not for 
LPS-induced signaling events (Crowley t al., 1997). The response of MAPK/ERK or 
MAPK/p38 activation to FcγR engagement was largely void in Syk-/- macrophages 
(Kiefer et al., 1998). In Syk-/- cells, FcγR-induced signaling events mediated through p85 
PI 3-kinase were attenuated, whereas they were essentially normal for signaling through 
Vav (Crowley et al., 1997). 
III. MAPKs Signaling Pathways 
            The MAPK signaling pathways are evolutionally well conserved in eukaryotes. 
They play important roles in many cellular processes including cell growth, 
differentiation, and apoptosis. They are essential modulators of both the innate and th
adaptive immune response. So far, four major MAPK pathways have been identified in 
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mammalian cells, i.e., MAPK/ERK, MAPK/p38, c-Jun NH2-terminal kinase 
(MAPK/JNK) and MAPK/ERK5 (Imajo et al., 2006). 
            The activation of all MAPK pathways is achieved through a core triple kinase 
cascade: MAPK kinase kinase (MKKK), MAPK kinase (MKK), and MAPK (Figure 5). 
MAPKs are activated upon phosphorylation on Thr and Tyr by MKKs. Activation of 
MKKs is initiated after phosphorylation on their Ser/Thr residues by MKKKs. To date, 
seven MKKs and 14 MKKK s have been identified. MKKKs are more diverse in their 
structures, and they can be differentially regulated by a variety of upstream stimuli that 
specifically regulate downstream MKKs. MKKs are highly specific for their substrates, 
which limits the variability of the MKK-MAPK part of the cascade. All the MAPKs 
consist of a Thr-X-Tyr (TXY) motif within their activation loop, and the phosphorylation 
of both threonine and tyrosine within the activation loop is essential and sufficient for 
their activation (Zhang and Dong, 2005). 
            MAPKs are the key mediators of eukaryotic transcriptional responses to 
extracellular signals as they can phosphorylate transcription factors, co-regulatory 
proteins and chromatin proteins. In this way MAPKs can influence DNA binding, protein 
stability, protein localization, transcription or repression, and nucleosome remodeling 
(Whitmarsh, 2007). 
MAPK/ERK  
            MAPK/ERK1 and 2 share 83% identity in their protein sequences, and they are 
ubiquitously expressed protein kinases in all tissue. MAPK/ERK1 is also known as 





Figure 5. Mammalian MAPK signaling pathway. Mammalian MAPK activation is achieved 
through MAP3K-MAP2K-MAPK cascade. Phosphorylated MAPK, MAPK/ERK, MAPK/p38 
and MAPK/JNK can activate a number of nuclear and cytoplasm kinases (RSK, MSK, MN
MAPKAPK, PRAK) and transcription factors (AP-1, ATF, CHOP, c-Myc, CREB, Elk-1, NF-AT 
and NF-κB).     
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p42 MAP kinase. They are essential in the regulation of cell growth, differentiation and 
proliferation. Mice lacking MAPK/ERK1 are viable, and it has been suggested that the 
function of MAPK/ERK1 can be fulfilled by MAPK/ERK2 in most cells except for T 
cells (Pages et al., 1999). T cell development after the CD4+CD8+ stage is retarded in 
MAPK/ERK1-/- mice. MAPK/ERK2 is essential for mesoderm differentiation and 
MAPK/ERK2-/- mice have major defects in early development (Yao et al., 2003).  The 
MAPK/ERK pathway can be activated by many stimuli including carcinogen agents, 
cytokines, growth factors, GPCR ligands, transforming compounds, and viruses. The 
Ras-Raf-MEK1/2-MAPK/ERK1/2 sequential activation is a typical process for activation 
of MAPK/ERK signaling pathway. Briefly, Ras is activated by the interaction of 
membrane-bound receptors with their corresponding ligands, allowing it to interact with 
downstream effector proteins such as the serine/threonine MKKK/Raf. Activated R f 
binds to and phosphorylates the dual specificity MKK/MEK1/2. MEK1/2 in turns 
phosphorylates MAPK/ERK1/2 at the conserved Thr-Glu-Tyr (TEY) motif within te 
activation loop (Chong et al., 2003). Two structurally unrelated compounds are 
commonly used to specifically block the MAPK/ERK1/2 pathway: PD98059 and U0126 
(Cuenda and Alessi, 2000). They are noncompetitive inhibitors of MEK1/2 and prevent 
activation of MAPK/ERK1/2.  
MAPK/ERK1/2 proteins are present throughout quiescent cells. Upon stimulation, 
a significant population of phosphorylated MAPK/ERK1/2 accumulates in the nucleus. 
The mechanisms of nuclear accumulation of MAPK/ERK1/2 remain largely unknown. It 
has been suggested that nuclear retention, dimerization, phosphorylation and release from 
cytoplasmic anchors are involved (Pouysségur et al., 2002). Nuclear localization of 
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activated MAPK/ERK1/2 indicates their important roles as “nuclear kinases” to act on 
nuclear substrates (Denhardt, 1996). Indeed, many nuclear proteins are identified as the 
substrates of MAPK/ERK, including nuclear factor of activated T- cells (NF-AT), Ets 
like gene1 (Elk-1), cellular FBJ murine osteosarcoma viral oncogene homolog (c-Fos), 
cellular v-myc myelocytomatosis viral oncogene homolog (c-Myc), cAMP response 
element binding protein (CREB) and STAT3. More importantly, three nuclear kinases, 
mitogen- and stress-activated protein kinase (MSKs), MAPK-intergratin  kinase (MNKs) 
and ribosomal protein S6 kinases (RSKs) are the substrates for MAPK/ERK1/2. Both 
MSKs and MNKs can be activated by both MAPK/ERK1/2 and MAPK/p38, while RSK 
family members are exclusively activated by MAPK/ERKs. Both MSKs and RSKs 
contribute to gene transcriptional regulation by phosphorylation of their corresponding 
substrates, whereas MNKs are mainly involved in the regulation of translation.  
MAPK/p38  
            The MAPK/p38 MAPK pathway is strongly activated by inflammatory cytokines 
such as IL-1 and TNF-α and also by environmental stress (Johnson and Lapadat, 2002). 
This pathway is associated with gene expression, cytokine production, inflammation, cell 
growth, cell differentiation and cell death. The MAPK/p38 pathway consists of several 
MKKKs, including MKKKs 1 to 4; the two MKKs, MKK3 and MKK6; and the four 
MAPK/p38 isoforms: α (MAPK14), β (MAPK11), γ (MAPK12) and δ (MAPK13). 
MAPK/p38α and MAPK/p38β are ubiquitously expressed. MAPK/p38γ is mainly 
expressed in skeletal muscle whereas MAPK/p38δ gene expression is found in the lung, 
kidney, testis, pancreas and small intestine. MKK3/6 exhibit high specificity towards 
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MAPK/p38. They do not activate other MAPKs such as MAPK/ERK1/2 and 
MAPK/JNKs. MKK3 is more selective than MKK6. MKK3 preferentially targets the 
MAPK/p38α and MAPK/p38β, while MKK6 can activate all MAPK/p38 isoforms. 
MKK3/6 specifically recognizes the activation loop of MAPK/p38 MAP kinases and 
phosphorylates a conserved Thr-Gly-Try (TGY) motif within the loop. The 
phosphorylated TGY motif and the length of the activation loop are two critical factors 
that contribute to the substrate specificity of MAPK/p38. Non-activated MAPK/p38 are 
found both in the nucleus and the cytoplasm of quiescent cells. MAPK/p38 can move 
from the cytoplasm to the nucleus after activation. Substrates for activated MAPK/p38 
include the protein kinases, MAPK-activated protein kinases 2/3/5 (MAPKAPK or MK 
2/3/5), MSK1/2, MNK1/2, casein kinase 2 (CK2) and the MAPK/p38-regulated/activated 
protein kinases (PRAK) as well as the transcription factors activating tra scription factor 
2 (ATF-1/2), cAMP response element-binding protein-homologous protein (CHOP)/ 
growth arrest DNA damage 153 (GADD153), myocyte enhancer factor (MEF), Elk-1, 
NF-κB and p53 (Dunn et al., 2005).  
            Although MAPK/p38 MAP kinase is regulated by MKK3, MKK4 and MKK6, 
MKK3 and MKK6 are specific for MAPK/p38 activation whereas MKK4 can activate 
both MAPK/p38 and MAPK/JNK. Thus MKK4 represents an integration point of stress-
activated MAPK pathways. The contribution of these MKKs to MAPK/p38 activation 
may vary among different cell types. It has been demonstrated that T-cell-receptor 
mediated MAPK/p38 activation is selectively defective in MKK3-/- CD4+ peripheral T 
cells and MKK6-/- thymocytes respectively due to the differences in the expression of 
MKK3 and MKK6 in these two cell types. Furthermore, the pool of protein kinases that 
 
 31 
contributes to MAPK/p38 activation can be dependent on the specific stimulus that is 
applied. Activation of MAPK/p38 caused by UV radiation needs all of three MKKs, i.e., 
MKK3, MKK4, and MKK6 whereas TNFα-initiated MAPK/p38 activation requires both 
MKK3 and MKK6 in fibroblasts, and MKK3 appears to be critical for LPS-mediat 
MAPK/p38 activation (Lu et al., 1999.). Activation of MAPK/p38 can also occur 
independent of MKKs as demonstrated by the studies of TAB1 (transforming growth 
factor-β-activated protein kinase-1 binding protein 1) (Ge et al., 2002; Ge et al., 2003). 
TAB1 binds and activates a MKKK, transforming growth factor-β-activated protein 
kinase 1 (TAK1), to subsequently activate both MAPK/p38 and MAPK/JNK MAPK 
pathway. TAB1 can also directly bind to MAPK/p38α to initiate MKK-independent 
autophosphorylation and activation of MAPK/p38α, particularly the splicing variant of 
TAB1, TAB1β that only binds to MAPK/p38α but not TAK1 to directly activate 
MAPK/p38α MAP kinase. It has been proposed that the MKK-independent activation of 
MAPK/p38 kinase by TAB1β contributes to the regulation of the basal level of 
MAPK/p38 activities and the activation of MAPK/p38 pathways mediated via 
membrane-bound receptors. 
            MAPK/p38α-/- mice are embryonic lethal (Mudgett  al. 2000). Studies have 
shown that in MAPK/p38α-/- mice embryonic fibroblasts, MK2 expression is decreased 
and in MK2-/- mice MAPK/p38α expression is significantly reduced. This implies that 
MAPK/p38α may form a complex with MK2 to stabilize each other. Due to its C-
terminal nuclear localization signal (NLS) and nuclear export signal (NES), MK2 can 
shuttle between nucleus and the cytoplasm. MK2 locates in the nucleus of non-stimulated 
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cells because its NES is masked. MK2 can be activated by MAPK/p38α and β to exposes 
its NES, which promotes MK2 translocation from nucleus to cytoplasm in a complex 
form together with MAPK/p38α. Phospho-MAPK/p38α and phospho-MK2 as a complex 
remains stable in the cytoplasm (Engel et al., 1998). Besides the co-exportation feature of 
MAPK/p38, MK2 also plays a role in actin remodeling, cell migration and development, 
regulation of the cell cycle (Manke et al., 2005), chromatin remodeling (Voncken t al., 
2005), and post-transcriptional regulation (see below for details).  MK2 can activate 
downstream cytoplasm substrates, such as heat shock protein (HSP) 25/27, lymphocyte-
specific protein 1, tyrosine hydroxylase and nuclear substrate, serum respons  factor 
(SRF) and mRNA-binding proteins.  
MAPK/JNK 
            MAPK/JNK1, 2 and 3, also known as MAPK8, 9, and 10 respectively, are 
characterized as stress-activated protein kinases because of their activation in response to 
inhibition of protein synthesis (Johnson and Lapadat, 2002). The expression of 
MAPK/JNK1 and MAPK/JNK2 was found to be ubiquitous, while the expression of 
MAPK/JNK3 is brain-specific. Although the canonical MAPK/JNK signaling pathway 
has been extensively characterized, the specific role of MKKK for MAPK/JN s in 
response to various cues still remains elusive (Weston and Davis, 2007). The MKKK 
isoform TAK1 is a critical kinase for MAPK/JNK activation in response to stimuli via 
TLR-3, -4 and -9. TAK1 is also important for MAPK/JNK activation mediated by 
inflammatory cytokines such as IL-1, transforming growth factor β (TGFβ), lymphotoxin 
B and TNFα. The B-cell receptor and the T-cell receptor-initiated activation of 
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MAPK/JNKs is also mediated via TAK1. It has been reported that the MKKK isoforms 
TPL2 and MLK3 are other upstream kinases activated by TNFα to initiate MAPK/JNK 
activation. TLR-8-triggered MAPK/JNK activation appears to be mediated via the 
MKKK isoform MEKK3. A major target for MAPK/JNKs is the transcription factor 
activator protein-1 (AP-1), which is composed of Fos and Jun family members. 
MAPK/JNKs are found to bind and phosphorylate c-Jun thereby increasing its 
transcriptional activity. c-Jun protein is a component of the AP-1 transcription complex. 
AP-1 is activated in response to all stimuli that activates MAPK/JNKs and co tributes to 
the regulation of many cytokine genes. Regulation of the MAPK/JNK pathway is 
extremely complex, and it is influenced by at least 13 MKKKs. After activation by 
MKKKs, both of MEK4 and MEK7 activate MAPK/JNKs by phosphorylation on 
tyrosine and threonine residues in a conserved Thr-Pro-Tyr (TPY) motif within the 
activation loop. 
Some experiments suggested that MAPK/ERK activation is required for Th2 
differentiation while MAPK/p38 protein kinase is required for both Th1 and Th2 
differentiation, and IFN-γ production (Rincón and Pedraza-Alva, 2003). The MAPK/p38 
protein kinase participates in macrophage and neutropil functional responses and 
mediates T-cell differentiation and apoptosis by regulating IFN-γ production. MAPK/p38 
protein kinase can also regulate the immune response by stabilizing mRNAs such as 
TNF-α. MAPK/JNK may reduce the proliferative response of activated CD4+T cells and 
polarize T cell differentiation to Th1 lineage. MAPK/JNK1-/- mice exhibited an 
exaggerated Th2 response which exacerbated Leishmaniasis with non-healing skin 
lesions (Constant et al., 2000). MAPK/JNK2-/- mice had low or no IFN-γ production. It 
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has been suggested that MAPK/JNK1 and MAPK/JNK2 may play different roles in 
CD8+T cell proliferation (Zhang and Dong, 2005).    
IV. Cytokine Gene Regulation 
Cytokine production from immune cells following a stimulus is controlled at 
different levels.  The regulation of gene transcription is achieved at the initiatio  of 
transcription by cis-elements within the regulatory regions of the DNA and trans-acting 
factors that include transcription factors and the basal transcription complex.  Regulation 
can occur at the epigenetics level where alterations in chromatin accessibility can expose 
cis-elements. Regulation can also occur at the post-transcriptional level, which includes 
mechanisms such as splicing to convert precursor mRNA into mature mRNA; regulation 
of transportation of mature mRNA into cytoplasm for cytokine synthesis (translatio ); 
control at mRNA degradation; regulation of posttranslational modification for maximum 
biological activity; and secretion of biological cytokines into extracellular sp ce. 
Transcriptional Regulation of Gene Expression  
            The cis-elements of the IL-10 promoter and the corresponding transcription 
factors that bind to it are conserved among all the cells that produce IL-10 (Mosser and 
Zhang, 2008). In the murine IL-10 gene promoter, a TATA box is located between 98 
and 95 bp upstream of the first methionine codon - the translational initiation site ATG. 
The transcriptional initiation site for murine IL-10 gene -ACA is located b tween 68 and 
66 bp upstream of ATG. A CCAAT box is found between -244 and -240 bp (CCAGT). 
Transcription factors, such as STAT3, specificity protein 1 (Sp1), IRF1, CREB, NF-κB 
and CCATT/enhancer-binding protein (C/EBP), all appear to be involved in IL-10 
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transcriptional regulation. Sp1 was originally identified to bind to GC-rich motifs in the 
SV-40 promoter and activate transcription n vitro in Hela cells (Jones and Tjian, 1985). 
Sp1 DNA binding domain is composed of 3C2H2 type zinc fingers. Sp1 is expressed 
ubiquitously and it can regulate many genes, including IL-1β, α2 collagen and TNF 
receptor expression. Using Sp factor-deficient Drosophila SL2 cells, the requirement for 
Sp1 in transcription of murine IL-10 gene was demonstrated (Tone et al., 2000; Brightbill 
et al., 2000). In addition to Sp1, the role of other transcription factors that have been 
shown to regulate IL-10 gene has recently been reviewed in details (Mosser and Zhang, 
2008). Table 2 is a brief summary of the sequence of their binding element(s) and the 
immune cells that are studied. 
Biosynthesis of the functional IL-12p70 heterodimer is mainly controlled at the 
regulation of IL-12p40 gene expression. The p40 gene is only expressed in IL-12-
secreting cells and is highly inducible. On the other hand, the p35 gene is expressed 
ubiquitously. The IL-12p40 promoter has been well characterized (Trinchieri G, 2003). It 
contains several elements that are functionally important for its inducible expr ssion. 
Several transcription factors have been identified to be essential for IL-12p40 gene 
expression in response to different stimuli. The ability of LPS-induced transcription of 
p40 gene is mainly via a nonconsensus NF-κB half-site in the proximal promoter region, 
and this NF-κB half-site is functionally synergistic with a downstream C/EBP site, 
although cooperative binding of Rel A/p65 and C/EBP proteins was not observed 
(Trinchieri G, 2003). Two E26 transformation-specific (ETS) family members, PU.1 and 
ETS2, bind to an ETS consensus elements upstream of the NF-κB site, and then this  
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TF Binding sites Cell distribution 
Sp1 AGGAGG Macrophage, monocyte, 
T cell, B cell 
STAT TCATGCTGGGATCTG 
ACCTTTGCCAGGAAGGCCCC 
NK, monocyte, T cell 
C/EBP TGGAGGAAACAATTATTTCTCAATCC 
TTATTTCTCAATCC 
Macrophage, monocyte, T 
cell 
IRF GCTAAAAAGAAA AAA 
AAAAAAGGGAAAGGAAA AAA 
AAAAGAAAGAAA TTA 




Macrophage, monocyte, T 
cell 




c-Maf TGCCTGGCTCAGCA Macrophage, monocyte 
T cell 





Table 2: Murine IL-10 promoter TF binding sites and cell distribution.
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complex can form a larger complex with c-REL and several IRF family members, 
including IRF1, IRF2 and IFN-consensus sequence-binding protein (ICSBP also known 
as IRF8). The IEF family members are essential for the transcription of IL-12p40 gene 
initiated by IFN-γ stimulation. Several inhibitors of IL-12 production have been shown to 
cast their effects via transcriptional repressors. GA12-binding protein (GAP12) is a 
repressor that interacts with GATA sequence in the IL-12 promoter (GA12) element in 
unstimulated cells. This GA12 element is located between the ETS and NF-κB sites, and 
IL-4 or prostaglandin E2 (PGE2) enhances the binding of GAP12 to GA12 elements to 
suppress IL-12p40 expression (Becker et al., 2001).  
            Like the IL-12p40 promoter, the IL-12p35 promoter also contains binding sites 
for PU.1, C/EBP and IFN-γ response element (γ-IRE). IFN-γ signaling induces the 
expression of IRF-family members such as IRF-1 and IRF-8 to induce the transcription of 
IL-12p35 gene (Liu et al., 2004). There are multiple transcription initiation sites in IL-
12p35 promoters, for example the human p35 gene has one site only for its expression in 
B cells whereas the other one is for its transcription in monocytes, indicating that 
differential cell-type may use different ones (Hayes et al., 1998). 
Epigenetic Regulation of Gene Expression 
            Histone are small, highly conserved basic proteins, found in the chromatin of all 
eukaryotic cells. They are associated with DNA to form nucleosomes. Core histones are 
histones H2A, H2B, H3 and H4. A nucleosome contains two copies of the core histones 
wrapped by 146-bp DNA. The DNA helix is wrapped around core histones to form a 
simple chromosome structure-“beads on a string” and then these fold into higher-order 
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chromatin. Chromatin is organized into two conformation domains, euchromatin (active) 
and heterochromatin (inactive), which have different chromosomal architecture, 
transcriptional activity and replication timing (Bernstein t al., 2007). How chromatin 
maintains its structure and how transcription factors find their target sequences remain 
largely unknown. The distinction between active and inactive chromatin in eukaryotic 
organisms can be made by epigenetic marking via DNA methylation and post-
translational modifications of core histones, which regulate transcription of the protein-
encoding genome. 
            Most post-translational modifications of core histones occur at the amino- and 
carboxy-terminal histone “tails”, and a few localize to the histone globular domains. 
These “tails” stick out of the nucleosome and are easily exposed for a variety of 
modifications. The resultant modifications account for a “histone code” and generat  
specific docking sites for other proteins to regulate chromatin structure and gene 
transcription (Strahl and Allis, 2000). Lysine is a key residue subjected to many
modifications, including acetylation, methylation, ubiquitination and SUMOylation. 
Acetylation and methylation result in attachment of chemical groups with small 
molecular weight, whereas large moieties are attached by ubiquitination and 
SUMOylation, usually about two-thirds the size of histone itself. In addition, methylation 
can occur several times on one lysine side chain, such as mono-, di-, or trimethylation.  
            Phosphrylation at serine and /or threonine residues is also critical for regulation of 
gene transcription. Histone H3 phosphorylation, particularly phosphorylation at serine10, 
has been extensively characterized. Histone H3S10 phosphorylation is correlated with 
either activated transcription (open chromatin) or mitotic chromosome condensation 
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(closed chromatin), i.e., in a genomic context-dependent fashion. Activation of 
MAPK/ERK or MAPK/p38 MAPK signaling pathways leads to a rapid and transient 
histone H3 phosphorylation at serine 10 (Thomson et al., 1999; Dyson et al., 2005). It 
occurs frequently in a minute fraction of total histone H3 that is associated with the 
promoter region of immediate early genes (Thomson et al., 1999; Dyson et al., 2005) and 
a subset of cytokines and chemokines (Saccani et al., 2001). Histone H3 phosphorylation 
increases the accessibility of the promoter region to transcription factors as the result of 
chromatin remodeling (Arbibe t al., 2007; Zhang et al., 2006). Macrophages stimulated 
with TLR ligands together with Fcγ receptor ligation display a rapid MAPK/ERK 
activation, resulting in a transient H3S10 phosphorylation on the nucleosomes that are 
associated with the IL-10 promoter to promote the rapid binding Sp1 to the IL-10 
promoter and subsequent IL-10 gene transcription (Lucas et al., 2005). 
            MAPK/ERK or MAPK/p38 MAPKs-induced histone H3 phosphorylation may be 
mediated through downstream histone H3 kinases, such as MSK1/2. MSK1/2 activation 
directly elicits histone H3 phosphorylation at Ser10 and Ser28 because MSK1/2 
recognizes a serine residue preceded by Ala-Arg-Lys. Phosphorylation at Ser10 of 
histone H3 is exceptionally sensitive to hyperacetylation caused by histone deacetylase 
inhibitors such as TSA (Dyson et al., 2005). Histone H3 Ser10 phosphorylation recruits 
HAT to acetylate Lysine 14 of histone H3 (Meyer, 2001). Histone phosphorylation and/or 
acetylation not only lead to conformational changes making proteins easily accessible to 
the promoter region, but also enhance their interactions with chromatin (Meyer, 2001). 
Post-transcriptional Regulation of Gene Expression 
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            Precursor RNAs must undergo post-transcriptional processing to become mature 
mRNAs.  This involves splicing, pre-mRNA 5' capping, and 3' polyadenylation. The 
concentration of mature mRNA in the cytoplasm, which depends on mRNA transport, 
storage and degradation, is critical for the translation. Elucidating the basic mechanisms 
of post-transcriptional regulation of gene expression is essential to gain a full 
understanding of how gene expression is regulated at different levels.  
               In the past decades, AU-rich elements (AREs) in the 3′-untranslated regions (3’-
UTR) have been demonstrated to affect mRNA stability and translation. It has been 
shown that the MAPK/p38 pathway is involved in regulating mRNA stability of many 
cytokine genes via their 3′-UTRs, including TNFα, IL-8, IL-6, and GM-CSF mRNAs 
(Brook et al., 2000; Winzen et al., 1999). The MAPK/p38 pathway is also implied to 
have a regulatory role on TNFα biosynthesis at the translational level via AREs in the 3’-
UTR of its mRNA (Winzen et al., 1999). 
            MAPK/p38 pathway exerts its action mainly through its downstream kinase, 
MK2. MK2 plays important roles to affect post-transcriptional regulation rather than gene 
transcription (Gaestel, 2006). Gaestel et al showed that MK2-/- mice were resistant to 
LPS-induced endotoxic shock due to a 90% reduction of TNFα (Kotlyarov et al., 1999) 
while deletion of the ARE in the 3’-UTR of the TNFα mRNA restored LPS-induced 
TNFα production (Neininger et al., 2002). The levels of IFN-γ, IL-1, IL-6 and nitirc 
oxide were also lower in MK2 knockout mice (Kotlyarov et al., 1999).    
            How MK2 regulates mRNA stability and translation remains elusive. A number 
of proteins are able to bind to mRNA and stabilize mRNA such as HuA-D/R (RNA-
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binding protein homologous to human A-D or R antigen), or destabilize mRNA such as 
AUF1 (AU-rich element binding factor), TTP (tristetraprolin), KSRP (K homology-type 
splicing regulatory protein), TIA-1 (T-cell restricted intracellular antigen-1) and TIAR 
(TIA-1-related protein). The MAPK/p38-MK2-TTP axis has been shown to control post-
transcription regulation of TNFα mRNA in LPS-stimulated cells. In quiescent cells, TTP 
binds to the ARE of TNFα mRNA in a non-phosphorylated form and destabilizes TNFα 
mRNA. After stimulation, activated MK2 phosphorylates TTP (Mahtani et al., 2001), and 
the phosphorylated TTP binds to 14-3-3 proteins to prevent the target mRNA from 
degradation. Macrophages derived from TTP-/- mice tend to produce more TNFα. Due to 
high secretion of TNFα and GM-CSF, TTP-/- mice have severe inflammatory syndromes, 
polyarticular arthritis, myeloid hyperplasia, and cachexia (Carballo et al., 1998). Hence, 
MK2 has a positive role to regulate TNFα mRNA stability by phosphorylation of TTP.  
            MK2 can also regulate TNFα biosynthesis at the translational level. Mammalian 
target of rapamycin (mTOR) is a serine/threonine protein kinase that regulates pro ein 
synthesis and transcription. mTOR function as the catalytic unit of two distinct 
complexes: mTORC1 and mTORC2. mTORC1 phosphorylates at least four residues of 
eukaryotic translation initiation factor 4E (elF4E)-binding protein-1 (4E-BP1). 
Phosphorylated 4E-BP1 releases eIF4E, allowing it to bind to 5’-capped mRNAs and 
recruit them to the ribosomal initiation complex for translation. TSC1 (tumor-suppressor 
proteins hamartin, also known as tuberous sclerosis)-TSC2 (tuberin) complex inhibits 
translation by inhibiting mTOR mediated 4E-BP1 phosphorylation. MK2 can 
phosphorylate TSC2 and the phosphorylated TSC2 binds to 14-3-3 proteins, which 
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reverses the inhibitory function of the TSC1-TSC2 complex on 4E-BP1 phosphorylation 
(Li et al., 2003). 
IL-10 mRNA contains a long segment of 3'-UTR: 702 bp for the murine IL-10. 
Deletion of its 3’-UTR makes IL-10 mRNA refractory to degradation (Powell et al., 
2000). The 3’-UTR of IL-10 mRNA contains six AUUUA pentamers, four of which are 
surrounded by U residues to form octameric motifs that are very similar to the class II 
AREs. TTP is known to bind to these AREs and trigger the rapid degradation of mRNA. 
In the primary macrophages obtained from TTP-/- mice, IL-10 mRNA decay rate is 
significantly reduced (Stoecklin et al., 2008). IL-10 production can also be regulated at 
the translational level. In LPS-stimulated macrophages, adenosine-mediated signals 
specifically relieve the translational repressive effects of the IL-10 mRNA 3'-UTR, 
without affecting IL-10 gene transcription and IL-10 mRNA stability (Németh t al., 
2005).   
It remains elusive how IL-12p40 or p35 gene expression is regulated at the level 
of mRNA stability. In a very recent study led by Akira and his colleagues, they identified 
an RNase, Zc3h12a, as a destabilization factor to control the stability of IL-12p40 mRNA 
(Matsushita et al., 2009). In response to TLR ligands, macrophages from Zc3h12a 
deficient mice had increased production of IL-6 and IL-12p40 but not TNFα as compared 
to the control littermates. The regulation of IL-12 biosynthesis is also controlled at the 
post-translational level. The p40 and p35 protein are processed by different mechanisms. 
Translocation of the p40 pre-protein into the ER is accompanied by cleavage of the signal 
peptide while removal of the p35 signal peptide occurs through two sequential cleavages 
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(Carra et al., 2000; Trinchieri, 2003). The first cleavage takes place in the ER at a site in 
the hydrophobic region of the signal peptide that is not affected by glycosylati n. The 
second cleavage may involve a metalloprotease after additional glycosylation and 
secretion of the p35 protein. This indicates that processing of p35 controls the output of 
biologically active IL-12 p70 heterodimer.   
In summary, the production of IL-12 and/or IL-10 from immune cells is regulated 
at multiple levels. In the past, many studies were more focused on their regulation at 
transcription level particularly the interaction of cis-elements within their promoter 
regions with trans-factors. More recent studies indicated that the regulation of he 
production of these cytokines could be achieved at the levels beyond transcription. Thus, 
thorough exploration of the underlying mechanisms responsible for the optimal 
production of these cytokines under different microenvironmental cues and the expected 
information would shed light on the understanding how innate and adaptive immunity is 
modulated in response to pathogens and would be beneficial for novel therapy to counter 
the diseases.  
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CHAPTER 2:  MATERIALS AND METHODS 
Mice  
            BALB/c, JH, and FcγR knockout female mice on the BALB/c background were
 
purchased from the National Cancer Institute Charles River Laboratories and Taconic 
Farms. DO11.10 mice, which have a transgenic T cell receptor (TCRαß) for OVA323-339, 
were purchased from the Jackson Laboratory and used as a source of antigen-specific 
CD4+ T cells. IL-10 knockout mice on the BALB/c background and MKK3 knockout 
mice on C57BL/6 background were purchased from the Jackson Laboratory. All mice 
were maintained in high efficiency particle air-filtered Thoren units (Thoren Caging 
Systems, Hazleton, PA) at the University of Maryland. All animal studies were reviewed 
and approved by the University of Maryland Institutional Animal Care and Use 
Committee.  
Reagents  
            All TLR ligands were obtained from InVivoGen (San Diego, CA). The 
MEK/MAPK/ERK inhibitors, U0126 and PD98059; the spleen tyrosine k ase (Syk) 
inhibitor (3-(1-methyl-1H-indol-3-yl-methylene)-2-oxo-2,3-dihydro-1H-indole-5-
sulfonamide) and another Syk inhibitor piceatannol; the Src family kinase inhibitor PP2; 
c-Raf inhibitor ZM336372 and the MAPK/p38 MAPK inhibitor, SB203580 and the 
structurally-related control compound SB202474 were all purchased from Calbiochem 
(EMD Biosciences, San Diego, CA). Low molecular weight hyaluronic acid (LMW-HA) 
(MP Biomedicals, Irvine, CA), Ultra-Pure LPS (Escherichia coli K12, InVivoGen, San 
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Diego, CA) and OVA (Worthington, Lakewood, NJ) were used to stimulate cells. Anti-
MAPK/ERK1/2 (total and phospho-T202/Y204) Abs, anti-MAPK/p38  (total and 
phospho-Thr180/Tyr182) Abs, and anti-MAPKAPK-2 Abs were obtained from Cell 
Signaling Technology. Anti-phosphorylated histone H3 (Ser10) Ab, anti-Sp1 Ab, and 
chromatin immunoprecipitation (ChIP) kits were purchased from Upstate Biotechnology. 
TRIzol reagent was purchased from Invitrogen Life Technologies. RNase-free DNase I 
was obtained from Roche Diagnostics.  
Cells 
            Bone marrow-derived macrophages (BMMφ) were prepared as previously 
described (Zhang et al., 2008). Briefly, bone marrow was flushed from the femurs and 
tibias of mice at 6–10 week of age. The cells were plated in petri dishes in DMEM/F12 
supplemented with 10% FBS, 1% glutamine, 1% penicillin/streptomycin, and 10% 
conditioned medium from the supernatants of M-CSF secreting L929 (LC14) fibroblasts 
(LCCM). Cells were fed on days 4. On day 7, cells were removed from petri dishes and 
cultured on tissue culture dishes in complete medium without LCCM. On the next day, 
cells were subjected to experiments.  
            Bone marrow-derived dendritic cells (BMDCs) were prepared similarly to the 
BMM φ as described above. However, the bone marrow cells were cultured in 
DMEM/F12 supplemented with 10% FBS, 1% glutamine, 1% penicillin/streptomycin, 
and 20% J588L cell conditioned medium that contains GM-CSF. Cells were fed on days 
2 and 5. On day 8, cells were collected from the medium and cultured on tissue culture 
dishes in complete medium without J588L cell conditioned medium.   
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            Peritoneal macrophages were collected by injecting 10ml PBS into mouse 
peritoneum as previously described (Zhang et al., 2008). Fluid was withdrawn from the 
peritoneum slowly.  The peritoneal exudate cells were centrifuged for 10 min at 300 × g 
4°C.  Supernatants were discarded and the cell pellet was resuspended in DMEM/F12-10 
supplemented with 10% FBS, 1% glutamine and 1% penicillin/streptomycin.  
            The RAW264.7 macrophage cell lines were obtained from the American Type 
Culture Collection (Manassas, VA). RAW264.7 cells were maintained in RPMI 
supplemented with 10% FBS, 1% glutamine and 1% penicillin/streptomycin.  
Parasites 
            Leishmania amazonensis (RAT/BA/72/LV78) (LA) and Leishmania major 
Friedlin strain, clone V1 (WHO MHOM/IL/80/Friedlin) were used. Parasites were 
maintained in BALB/c mice and cultured in vitro. Amastigotes are isolated from fo tpads 
of BALB/c mice that are infected for 6 to 8 weeks. Infected footpads were harv sted in 
cold PBS containing 200 U of penicillin-6-potassium per ml and 200µg of streptomycin 
sulfate per ml (PBS-pen/strep), after removal. Footpads were ground by the plungr of a 
10 ml syringe to pass through a cell strainer of 100µm nylon (BD Biosciences, San Jose, 
CA) in the presence of Schneider’s complete medium and resuspended in 10 ml of PBS-
pen/strep. The release of amastigotes from infected cells was achieved by passing the 
mixture through progressively smaller, 21-, 23-, and 25- gauge needles. Footpad-derive  
amastigotes were obtained by centrifugation at 1000×g for 10 min at 4°C.  
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            Stationary phase promastigotes of L. amazonensis were obtained by growing 
parasites in Schneider’s complete medium [Schneider’s insect medium (Sigma-Aldrich, 
St. Louis, MO) supplemented with 20% FBS, 100 U/ml penicillin, 100 µg/ml 
streptomycin, and 2 mM glutamine] at 25°C. IgG-free amastigotes of L. amazonensis 
were developed by axenic culturing in Schneider’s insect medium with 5% FBS, 100 
U/ml penicillin, 100 µg/ml streptomycin and 2 mM glutamine of pH 5.6 at 32°C. L major 
promastigotes were grown in 50:50 media [50% Schneider’s complete medium and 50% 
M199 media (Invitrogen, Rockville, MD)].  
Pre-treatment of Cells with MAPK Inhibitors and Stimulation 
            Cells were plated overnight in complete medium without LCCM. Cells were 
treated with MEK/MAPK/ERK inhibitors-U0126 or PD98059; Syk inhibitor and another 
Syk inhibitor-piceatannol; the Src family kinase inhibitor-PP2; c-Raf inhibitor-
ZM336372 or MAPK/p38 inhibitors: SB203580 or SB202474 for 30 minutes to 1 hour. 
Cells were then stimulated with either 10µg/ml LMW-HA or 10ng/ml LPS alone or in 
combination with the different forms of parasites for indicated times. 
Western Blotting Analysis 
            A total of 2×106 BMMφ per well were plated overnight in 6-well plates. Cells 
were activated with different stimuli in a final volume of 1ml of DMEM/F12 without 
L929 conditioned medium for the indicated times. Cells were then lysed in ice-cold lysis 
buffer (100 mM Tris (pH 8), 2 mM EDTA, 100 mM NaCl, 1% Triton X-100 containing 
complete EDTA-free protease inhibitors from Roche Diagnostics, which included 5 mM 
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sodium vanadate, 10 mM sodium fluoride, 10 mM β-glycerophosphate sodium, and 5 
mM sodium pyrophosphate). Equal amounts of protein were loaded onto 10% SDS-
polyacrylamide gels, and then transferred to polyvinylidene difluoride membranes. 
Membranes were incubated with primary Abs (1/1000 in 5% BSA in TBS-Tween 20) 
overnight at 4°C, washed, and incubated with secondary Ab (1/5000) with HRP 
conjugates. The specific protein bands were visualized by using Lumi-LightPLUS 
chemiluminescent substrate (Roche Diagnostics, Indianapolis, IN).  
Cytokines Measurement by ELISA 
            Approximately 2–5 x 105 cells were plated per well overnight in a 48-well plate. 
Cells were then stimulated and supernatants were harvested at different time i ervals. 
Cytokines were measured by a sandwich ELISA using antibody pairs (IL-12p40, IL-10, 
TNFα, IL-12p70, IFN-γ and IL-4, BD Pharmingen, San Diego, CA) according to the 
manufacturer’s instructions.  
Immunofluorescence Microscopic Analysis  
            Amastigotes were stained with 5 µM CellTracker Blue CMAC (Invitrogen Life 
Technologies, Carlsbad, CA). BMMφ were infected with amastigotes in the presence or 
absence of LMW-HA for a period of time. After brief washing with PBS, cells were fixed 
in methanol at 4°C for 15 min and then washed with PBS. Monolayers were incubated 
with 10% FBS in PBS for 1 h at room temperature to prevent nonspecific binding. 
MAPK/ERK1/2 phosphorylation was stained by a phospho-p44/42 MAPK (T202/Y204) 
(E10) mouse mAb (Alexa Fluor 488 conjugate) (Cell Signaling Technology, Danvers, 
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MA). Macrophages were counterstained for 2 min with 0.5% propidium iodide (PI). 
Slides were examined by using a Zeiss Axioplan 2 fluorescent imaging research 
microscope and Zeiss KS300 imaging software.  
RNA Isolation and Quantitative Real-time PCR (qRT-PCR)   
            TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA) was used to extract 
RNA from BMMφ (3-4 x106 cells per reaction). Homogenization was conducted to 
facilitate RNA extraction from footpad and lymph node. RNase-free DNase I (Roche 
Diagnostics, Indianapolis, IN) was used to remove contaminated DNA. ThermoScript 
RT-PCR system (Invitrogen Life Technologies, Carlsbad, CA) was used to generate 
cDNA from RNA by using random hexamers (for premature mRNA) or oligo(dT)20 (for 
mature mRNA). Sequences of primers are shown in Table 3. qRT-PCR was used to 
measure both mature and premature IL-10, IL-12p40 and TNFα mRNA levels. The 
mRNA levels are presented as arbitrary units that are derived from normalization values 
of each represented mRNA by corresponding GAPDH mRNA. The levels of mRNAs at 
zero hour were arbitrary set at 1. qRT-PCR was performed on an ABI Prism 7700 
Sequence Detection System or Roche LightCycler 480 Sequence Detection System using 
SYBR Green PCR reagents purchased from Bio-Rad Laboratories (Hercules, CA).  
Chromatin Immunoprecipitation (ChIP) Assay  
            ChIP assays were conducted using the ChIP Assay kit following the 
manufacturer’s protocol (Upstate Biotechnology-Millipore Inc., Billerica, MA) with 






premRNA IL-10 5'-CATTCCAGTAAGTCACACCCA-3' (intronic primer) 
5'-TCTCACCCAGGGAATTCAAA-3' 
premRNA IL-12p40 5'-TCTGAGCCACTCACATCTGCT-3' (intronic primer) 
5'-GGCCAATGAGAGTTCCTGTT-3' 
premRNA GAPDH 5'-TGTTCCTACCCCCAATGTGT-3' 
5'-TCCCAAGTCACTGTCACACC-3' (intronic primer) 
mRNA IL-10 5'-AAGGACCAGCTGGACAACAT-3' 
5'-TCTCACCCAGGGAATTCAAA-3' 
mRNA IL-12p40 5'-GGAGGTCAGCTGGGAGTACC-3' 
5'-AGGAACGCACCTTTCTGGTT-3' 
mRNA TNFα 5'-AAAGGGATGAGAAGTTCCCAAAT-3' 
5'-GTCTTTGAGATCCATGCCGTTG-3' 
nucleosomes 2 5'-GCAGAAGTTCATTCCGACCA-3'  
5'-GGCTCCTCCTCCCTCTTCTA-3' 
nucleosomes 11 5'-GTTGCTTCGCTGTTGGAAA-3'  
5'-GGTCAGTTCCAGGCTGAGTT-3' 
LA 18S rRNA 5'-AGCAGGTCTGTGATGCTCCT-3'  
5'-GGACGTAATCGGCACAGTTT-3' 
L.major 18S rRNA 5'-ATCGGCATCATCAGCGGCGG-3'  
5'-TCGACGGGTGGCCAATGTGC-3' 
murine 18S rRNA 5'-CCCAGTAAGTGCGGGTCATA-3'  
5'-AGTTCGACCGTCTTCTCAGC-3' 
mRNA MAPK/p38α 5'-AAGACTCGTTGGAACCCCAG-3'  
5'-TCCAGTAGGTCGACAGCCAG-3' 
mRNA MAPK/p38β 5'-AAGCCCAGTGTCCCTCCTAA-3'  
5'-CCACAGGCAACCACAAATCT-3' 
mRNA MAPK/p38γ 5'-GCTCACCCCTTCTTTGAACC-3'  
5'-TTCGTCCACGCTGAGTTTCT-3' 
mRNA MAPK/p38δ 5'-AGCCCTCAGGCTGTGAATCT-3'  
5'-CATATTTCTGGGCCTTGGGT-3' 
mRNA GAPDH 5'-TGTTCCTACCCCC AATGTGT-3' 
5'-GGTCCTCAGTGTAGCCCAAG-3' 
mRNA HPRT 5'-AAGCTTGCTGGTGAAAAGGA-3' 
5'-TTGCGCTCATCTT AGGCTTT-3' 
 
Table 3: Polymerase chain reaction primers pairs used in qRT-PCR analysis. 
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were plated overnight in six-well plates. Cells were stimulated and then fixed for 10 min 
at 37°C in 1% paraformaldehyde. Cells were washed on ice with ice-cold HBSS 
containing 1 mM PMSF, harvested and then lysed in SDS lysis buffer. DNA was sheared 
by ultrasonication using a High Intensity Ultrasonic Processor (Cole-Parmer, Vernon 
Hills, IL) for  3 x 10 s pulses at 20% amplitude that resulted in relatively uniform DNA 
fragment size of ~300 bp. Lysates were cleared by centrifugation and diluted in ChIP 
dilution buffer. Lysates were pre-cleared using salmon sperm DNA/protein A-agarose 
and a sample of "input DNA" was collected at this point. Protein-DNA complexes were 
immunoprecipitated with 5 µg of Ab overnight at 4°C. Ab-protein-DNA complexes were 
then captured using salmon sperm DNA/protein A-agarose for 1 h at 4°C. After washing 
beads with low and high salt, LiCl, and TE buffers, the protein/DNA complexes were 
eluted using 1% SDS, 0.1 M NaHCO3 buffer and
 disrupted by heating at 65°C for 4 h. 
DNA was then extracted using phenol/chloroform extraction and ethanol precipitation. 
For relative quantitation of promoter levels, qRT-PCR was performed.         
Infection and Parasite Quantitation  
              Mice were inoculated in the right hind footpad with different numbers of parasites, 
as indicated in the figure legends. Lesion size was measured with a digital caliper 
(Chicago Brand Industrial, Fremont, CA) and expressed as the difference in thickness 
between the infected and the contralateral (non-infected) footpad.  
            Parasite burdens were determined by a limiting dilution of cell suspensions 
obtained from excised lesions, as described previously. The parasite suspension was then 
7 times serially diluted in 10-fold dilutions in 200-µl Schneider’s complete medium in 
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96-well plates. Plates were incubated for 7 days at 25°C, and then the wells were 
inspected for the growth of promastigotes. Results were expressed as -log parasite titer. 
Parasite burdens were expressed as the negative log10 dilution of which
 parasite growth 
was visible. 
             qRT-PCR method was used to amplify parasite DNA as a second measure of 
parasite burdens. In brief, the homogenates of infected lesion were treated with proteinase 
K at 56°C for 48 hours. The DNA was obtained after phenol/chloroform extraction and 
NaOAC/EtOH precipitation. Primers specific for LA 18S rRNA gene and murine 18S 
rRNA gene were designed. The parasite burden was expressed as a fold change by using 
the ∆∆CT (cycle threshold)
 methods, as described below.  For quantitation of parasite 
burdens in the infected lesion, the CT value for murine 18S rRNA gene is used as 
normalization reference gene. 
Data Analysis  
            The relative differences among qRT-PCR samples were determined usi g the 
∆∆CT methods as described before (Zhang et al., 2006). A ∆CT value was determined for 
each sample using the CT value from input DNA to normalize ChIP assay results. The
 CT 
value for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or hypoxanthine-
guanine phosphoribosyltransferase (HPRT) gene was used to normalize loading in the 
RT-PCRs. For quantitation of parasite burden in the infected lesion, the CT value for 
murine 18S rRNA gene was used as normalization reference gene. A ∆∆CT value was 
then obtained by subtracting control ∆CT values from the corresponding experimental 
∆CT. The
 
∆∆CT values were converted to fold difference compared with the
 control by 
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raising 2 to the ∆∆CT power. Unpaired Student’s
 t test was used for statistical analysis. 
Values of p < 0.05 were considered to be statistically significant.  
RNA Stability Assay 
            2-3×106 BMMφ were stimulated for 2 hours before the addition of actinomycin D 
to a final concentration of 10 µg/ml. The degradation of IL-10, IL-12p40 and TNFα 
mRNA was subsequently measured by qRT-PCR over the following 4 hours. 
Transient Transfection and IL-12p40 Promoter Luciferase Assay 
            A fragment that contains mouse IL-12p40 promoter region was subcloned into the 
pGL3-basic luciferase expression vector (Promega, Madison, WI). Transient transfection 
assays in RAW264.7 macrophage-like cells was conducted using FugenHD reagent 
(Roche Diagnostics, Indianapolis, IN) following the manufacture’s recommendation. The 
pRL-TK construct (Promega, Madison, WI) was used as an internal control for 
normalization of transfection efficiency. Cell lysis and luciferase assays were performed 
using the dual luciferase assay system following the instructions f the manufacturer 
(Promega, Madison, WI). 
Generation of Small Interfering RNA (siRNA) and Cell Transfections  
            SignalSilence® MAPK/p38 MAPK siRNA Kit (Cell Signaling, Danvers, MA) 
was used to knock down endogenous MAPK/p38 proteins. For cell transfections, 5 x 106 
primary BMMφ were transfected with different dose of siRNA using the Amaxa 
Nucleofector system (Lonza Cologne AG, Basel, Switzerland) and stimulated 48 h later 
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as described before (Zhang et al., 2009). Gene silencing was confirmed by western blot 
analysis and qRT-PCR.  
T cell Isolation and Stimulation 
            Spleen or lymph nodes were removed from mice and placed in a petri-dish filled 
with PBS. A single cell suspension was obtained after the spleen or lymph nodes were 
meshed with a plunger of 5-ml syringe through cell strainer of 100µm nylon (BD 
Biosciences, San Jose, CA). Pan T Cells Isolation Kit (Miltenyi Biotec Inc, Auburn, CA) 
was used to obtain T cells from these single cell suspension solutions following the 
manufacture’s recommendation.  
Bone marrow-derived macrophages (2 x 105/well) were seeded in a 48-well plate 
and primed with IFN-γ (100 U/mL, R&D Systems, Minneapolis, MN) overnight. The 
primed cells were then treated with different stimuli as described in the figur legends for 
additional 16 hrs. The supernatants were collected for ELISA measurement and the
stimulated macrophages were filled with 0.5 ml of fresh medium (RPMI 1640 
supplemented with 10% FCS, HEPES pH 7.4, glutamine, Pen/Strep and 50 µM 2-
mercaptoethanol). The isolated T cells (5 x 105/well) were then added to each well to 
reach a final concentration of 0.6 ml for further incubation. After 3 days, the supernatants 
were collected from the T cell-macrophage incubation for ELISA measur ments of 
released cytokines as indicated in the figure legends. 
 Cytokine production by cells from lymph nodes obtained from infected BALB/c 
mice was determined using ELISA. Lymph nodes were removed from mice on day 56 
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post-infection and stimulated with anti-CD3 (BD Pharmigen, San Jose, CA) and anti-
CD28 (BD Pharmigen, San Jose, CA) for 48 hours. Then the cells were stimulated with 
PMA (Calbiochem, San Diego, CA) for 5 hours. Supernatants were harvested after 3 days 
and assayed for IFN-γ and IL-4 by ELISA.  
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CHAPTER 3: THE ROLE OF MAPK/ERK IN IL-10 PRODUCTION BY 
REGULATORY MACROPHAGES 
            Alterations of intracellular signaling pathways in host macrophages infected by 
Leishmania has been reported (Nandan et al., 2000) and implicated in promoting 
Leishmania pathogenesis (Reiner, 1994). Most of the alterations pertain to signaling 
pathways that trigger macrophages to eliminate parasites. The super-inductio  of IL-10 
has proven to be one of the most important factors in progressive Leishmaniasis. The 
surface IgG on Leishmania amastigotes allows them to ligate FcγRs on macrophages 
causing these macrophages to preferentially induce high amounts of IL-10. The IL-10 
produced by infected macrophages prevents macrophages activation and diminishes the 
production of IL-12. It has been demonstrated that MAPK/ERK activation is a critical 
event in IL-10 super-induction. Therefore my hypothesis is that MAPK/ERK activation 
in host macrophages infected by parasites plays an essential role in Leishmaniasis. To test 
this hypothesis, we examine MAPK/ERK activation in macrophages infected wih L. 
amazonensis (LA).  
MAPK/ERK Activation Correlates with IL-10 Production in Leishmania-infected 
Macrophages 
            We examined MAPK/ERK activation in macrophages infected with different 
forms of LA by western blotting (Figure 6A).  Stationary phase promastigotes and axenic 
amastigotes were both relatively inefficient at inducing MAPK/ERK activ tion in 





Figure 6. MAPK/ERK activation and IL-10 production in infected macrophages. A, 
Stationary-phase promastigotes, axenic cultured amastigotes, and footpad derived amastigotes 
were obtained, as described in Materials and Methods. They were added to monolayers of 
BMMφ (2 x 106 cells/well), along with hyaluronic acid (HA) (10 µg/ml). The ratio of parasites to 
macrophages was 20:1. At designated times, equal amounts of whole cell lysat s (15 µg) were 
subject to electrophoresis on 10% SDS-PAGE. Phosphorylated forms of MAPK/ERK and the 
corresponding total proteins were detected by Western blotting. B, Macrophages were treated 
with HA (10 µg/ml), or infected with stationary promastigotes (Promastigotes), axenic 
amastigotes (A. Amastigotes), footpad derived amastigotes (Fp. Amastigotes), or Fp. amastigotes 
and HA. Supernatants were collected after 16 h, and IL-10 was quantitated by ELISA. Data 
represent one of three independent experiments (mean ± SD of triplicates). 
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transient MAPK/ERK phosphorylation. They activated MAPK/ERK as early as 2 mins, 
then reached the peak between 5 to 10 mins and declined after 20 mins post-stimulation. 
The inflammatory extracellular matrix cleavage product, low molecular weight 
hyaluronic acid (LMW-HA), also induced MAPK/ERK activation, but this induction was
somewhat slower than footpad amastigotes, as late as 20 mins. LMW-HA (HA), which 
occurs at the inflammation sites, has been identified as TLR2/4 ligands (Termeer t al., 
2002).  
            MAPK/ERK activation was next correlated with IL-10 production by 
macrophages (Figure 6B). Infection of macrophages with either promastigotes or axenic 
amastigotes failed to induce IL-10 production, which is consistent with their failure to 
activate MAPK/ERK. Either HA or footpad-derived amastigotes alone yields little or no 
measurable IL-10 although both of them were able to induce MAPK/ERK activation. The 
combination of these two signals, however, resulted in production of high amounts of IL-
10.  
            To establish a link between MAPK/ERK activation and IL-10 production, 
macrophages were pretreated with U0126, an inhibitor of MEK (the upstream MAPKK 
which activates MAPK/ERK), and then infected with lesion-derived amastigotes plus 
HA. MAPK/ERK1/2 phosphorylation was strongly inhibited by U0126 at 2µM (Figure 
7A). There were also a dose dependent inhibition of IL-10 production by U0126 with IC50 
about 2µM (Figure 7B). As a control, IL-12p40 levels were also measured. There was a 
reciprocal increase of IL-12p40 that correlated with MAPK/ERK inhibition. 




Figure 7. MAPK/ERK activation by LA amastigotes. A, Macrophages were pretreated with or 
without U0126 (2 µM) for 1 h. Cells (2 x 106 cells) were then stimulated with HA plus lesion-
derived amastigotes for the indicated times. Electrophoresis and Western blotting were 
performed, as described above. B, Macrophages were pretreated with increasing concentrations of 
U0126 as indicated for 1 h and then infected with lesion-derived amastigotes in th  presence of 
HA (10 µg/ml) for 8 h. Supernatants were harvested, and IL-10 and IL-12p40 production were 




These data indicate that MAPK/ERK was required for IL-10 production by 
infected macrophages and inhibition of MAPK/ERK activation prevented IL-10 
production. In order to obtain decent amount of IL-10, two signals are needed: lesion-
derived amastigotes and an inflammatory stimulus such as HA.   
The Role of IgG in MAPK/ERK Activation by Leishmania  
            Axenically cultured amastigotes cannot activate MAPK/ERK but the lesion-
derived amastigotes that have IgG on their surface can (Figure 6A). To determine the 
relationship between surface IgG and MAPK/ERK activation, axenic amastigotes were 
opsonized with antibodies against LA and then added to macrophages. MAPK/ERK 
activation in the absence or presence of HA was analyzed (Figure 8A). Opsonized axenic 
amastigotes induced MAPK/ERK phosphorylation t  a similar degree and with similar 
kinetics as footpad derived amastigotes. In the presence of HA opsonized amastigotes 
increased the speed, magnitude and duration of MAPK/ERK phosphorylation. 
MAPK/ERK activation was detectable as early as 2 mins and persisted until 90 mins. 
Similar to the lesion-derived footpad amastigotes, opsonized axenic amastigotes 
only induced IL-10 production from acrophages in the presence of HA. Under these 
conditions, IL-10 production was induced in a parasite number-dependent man er (Figure 
8B, white bars). At a multiplicity of infection (MOI) between 10:1 and 20:1, a modest 
level of IL-10 was induced. HA was a potent inducer of IL-12, as previously reported 
(Hodge-Dufour et al., 1997). The addition of opsonized axenic amastigotes reduced IL-12 





Figure 8. Opsonized axenic cultured amastigotes activate MAPK/ERK and induce IL-10 
production. A, Macrophages (2 x 106 cells) were infected with LA axenic amastigotes opsonized 
with anti-Leishmania serum (Opsonized A. Am.) in the presence or absence of HA (10 µg/ml). 
Western blotting of phosphorylated MAPK/ERK1/2 was examined at the indicate  times. Total 
MAPK/ERK1/2 was used as the loading control. The ratio of parasites to macr ph ges was 20:1. 
B, Macrophages were infected with increasing concentrations (MOI from 1:1 to 40:1) of axenic 
cultured amastigotes opsonized with IgG (Op. A. Am.) in the presence of HA (10 µg/ml). The 
supernatants were collected after 16 h, and IL-10 and IL-12p40 proteins were determin d by 
ELISA. For controls, macrophages were treated with medium alone, opsonized axenic 
amastigotes (Op. A. Am.), or HA alone. Data represent one of three independent xp riments 
(mean ± SD of triplicates). C, Macrophages (2 x 105 cells) were exposed to a 20:1 ratio of 
opsonized axenic cultured amastigotes (Op. A. Am.) in the presence of increasi g concentrations 
of HA. Parallel monolayers were treated similarly, except that the MEK inhibitor, PD98059 (10 
µM), was added 30 min before stimulation. The supernatants were collected 8 h later, and IL-10 
concentrations were determined by ELISA. Data represent one of three indep ndent experiments 
(mean ± SD of triplicates).  
 
 62 
was administered to confirm this. Opsonized amastigotes induced IL-10 from 
macrophages in a HA dose-dependent manner, and this production was inhibited by 
PD98059 (Fig. 8C). These data showed that IgG is required for MAPK/ERK activation 
and its corresponding IL-10 production in LA infected macrophages. 
MAPK/ERK phosphorylation was also monitored by fluorecence microscopy. 
Macrophages were infected with footpad lesion-derived amastigotes (MOI=10:1) in the 
presence of HA. MAPK/ERK phosphorylation was detected by a fluorescence-labeled Ab 
against phosphorylated MAPK/ERK 1/2 (green). Amastigotes were prestained with Cell 
Tracker Blue (blue) and nuclei were stained with PI (red). Similar to what have been 
shown by western blot (Figure 6A), MAPK/ERK was activated in a time dependent 
manner, which could be detected as early as 2 mins and reached the maximal levels by 
20–30 mins post-infection (Figure 9A). Phosphorylated MAPK/ERK translocated to the 
nucleus, which is consistent with previous observations (Plows et al., 2004). A similar 
degree of MAPK/ERK activation occurred with opsonized axenic amastigotes (Figure 
9B). Axenic amastigotes were inefficient activators of MAPK/ERK compared to 
opsonized amastigotes at 15 mins post-infection.  
FcγR Mediated Syk Signaling Pathways is Involved in MAPK/ERK Activation by 
Opsonized Parasites  
Since IgG binds to FcγR, the next approach was to examine the role of FcγR in 
MAPK/ERK activation by using FcR γ-/- mice lacking the common γ chain through which 
FcγRI, III and IV signal. MAPK/ERK activation was undetectable following infection 
with lesion-derived amastigotes in these knockout cells compared to the wild type cells 
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Figure 9. Immunofluorescence analysis of MAPK/ERK activation in macrophages. A, 
Macrophage monolayers (1 x 105 cells/coverslip) were infected with lesion-derived footpad 
amastigotes in the presence of HA (10 µg/ml) at MOI of 10:1 for the indicate  times. Cells were 
fixed with cold-methanol, and visualized by fluorescence microscopy. Parasites were prestained 
with Cell Tracker Blue (blue). Phosphorylated MAPK/ERK was stained with mouse mAb (Alexa 
Fluor 488 conjugate) against phosphor-MAPK/ERK (green), and cell nuclei wer  stained with PI 
(red). B, Macrophages (1 x 105 cells) were treated with HA (10 µg/ml), and infected with 
unopsonized (A. Am.) or IgG-opsonized axenic cultured amastigotes (Op. A. Am.), in the 
presence or absence of HA for 15 min.   
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(Figure 10A). IL-10 production was significantly reduced after stimulation with varied 
MOI of opsonized parasites and HA in FcRγ-/- cells (Figure 10B).  Therefore, 
Leishmania- induced MAPK/ERK activation and IL-10 production are mediated through 
FcγR signaling pathway.  
            The kinases that are upstream of MAPK/ERK activation were examined. Syk is a 
tyrosine kinase that has been implicated in ITAM-mediated signaling via FcγR. 
Hypothetically the inhibition of Syk would lead to an inhibition of MAPK/ERK 
activation and subsequent IL-10 induction if opsonized parasites were mediated by FcγR-
Syk signaling pathway. A Syk inhibitor, 3-(1-Methyl-1H-indol-3-yl-methylene)-2-oxo-2, 
3-dihydro-1H-indole-5-sulfonamide, significantly reduced lesion-derived amastigotes 
induced MAPK/ERK activation in a dose-dependent manner (Figure 11A). At 1µM Syk 
inhibitor concentration, IL-10 production was reduced by greater than 80% (Figure 11B). 
Another Syk inhibitor, piceatannol, and the Src family kinase inhibitor PP2 were also 
tested (Figure 11B). IC50 for Syk inhibitor is only 0.024µM while piceatannol is 10.6µM 
and PP2 is 23.67µM.  
c-Raf has been identified as an upstream MAP3K that is responsible for 
MAPK/ERK activation in the well-defined Ras-Raf-MEK-MAPK/ERK signaling 
pathway. A c-Raf inhibitor, N-[5-(3-Dimethylaminobenzamido)-2-methylphenyl]-4-
hydroxybenzamide (ZM336372, IC50=70nM) was used to examine whether c-Raf was 
responsible for FcγR-mediated MAPK/ERK activation and IL-10 production. ZM336372 
had no effect on parasite-mediated MAPK/ERK activation (Figure 12A) with only a 





Figure 10. FcγR-mediated signaling is critical for MAPK/ERK activation. A, Macrophages 
derived either from BALB/c or FcR γ–/– mice were treated with different MOIs of opsonized 
axenic cultured amastigotes (Op. A. Am), as indicated. After 10-min incubation, cell lysates were 
collected and analyzed by Western blotting. B, Macrophages derived either from BALB/c or FcR 
γ–/– mice were infected with increasing amounts (MOI) of opsonized axenic cultured amastigotes 
together with HA (10 µg/ml). After 8 h, the supernatants were collected for ELISA to determine 






Figure 11. FcγR-mediated MAPK/ERK activation is signaled through Syk. A, Macrophages 
were pretreated with different doses of Syk inhibitor for 1 h and then stimulated with lesion-
derived amastigotes (MOI = 20:1) for 10 min. Whole cell lysates were coll cted and analyzed by 
Western blotting to detect MAPK/ERK phosphorylation. B, Macrophages were pretreated with 
Syk inhibitor (squares), piceatannol (triangles) and PP2 (circles) at different concentrations 30 
mins before exposed to a 20:1 ratio of opsonized amastigotes in the presence of HA. The 
supernatants were collected 6 hrs later, and IL-10 concentrations were determin d by ELISA. 
Data represent one of three independent experiments (mean ± SD of triplicates). 
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Figure 12. FcγR-mediated MAPK/ERK activation does not involve c-Raf.  A, Macrophages 
were pretreated with different doses of ZM336372 for 1 h and then stimulated with lesion-derived 
amastigotes (MOI = 20:1) for 10 min. Whole cell lysates were collected and analyzed by Western 
blotting to detect MAPK/ERK phosphorylation. B, Macrophages were pretreated with Syk 
inhibitor (black circles) or ZM336372 (white circles) at different con entrations 30 mins before 
exposure to a 20:1 ratio of opsonized amastigotes in the presence of HA. The supernatants were 
collected 6 hrs later, and IL-10 concentrations were determined by ELISA. Data represent one of 
three independent experiments (mean ± SD of triplicates). 
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that opsonized parasites activated MAPK/ERK through FcγR-mediated Syk activation 
that is independent of the Ras-Raf pathway.   
Induction of IL-10 Gene Expression by Opsonized Parasites Along with HA 
            The molecular mechanisms of IL-10 gene expression were studied in detail.  
Nuclear pre-mRNA and cytoplasmic mature mRNA was isolated from infected 
macrophages. Pre-mRNA formation and the accumulation of cytoplasmic mature mRNA
were both examined by qRT-PCR. In the presence of HA, opsonized amastigotes induced
IL-10 transcription (Figure 13A). Pre-mRNA transcripts were detected as early as 15 
minutes post-infection and reached the peak at around 1 hour. They returned to base level 
by 3 hours. Mature IL-10 mRNA was induced much later than the pre-mRNA. It became 
detectable 1 hour after infection and reached maximal level at 3 hours. IL-12p40 gene 
expression was undetectable under the same conditions. A similar phenomenon was 
observed using footpad-derived amastigotes. MAPK/ERK inhibition by U0126 prevented 
both transcription of IL-10 gene (Figure 13B) and accumulation of mature IL-10 mRNA 
(Figure 13C) from infected macrophages. These data demonstrate that MAPK/ERK 
activation is required for IL-10 transcription in response to Leishmania infection along 
with HA. 
MAPK/ERK Activation Results in Histone Phosphorylation at the IL-10 Promoter 
            Epigenetic modulation of IL-10 gene expression was investigated to further 
explore the molecular mechanisms of IL-10 transcription by ChIP assays. Our previous 






Figure 13. Parasites induce IL-10 gene expression via MAPK/ERK activation. A, 
Macrophages (4 x 106 cells) were treated with opsonized axenic cultured amastigotes (Op. A. 
Am.) (MOI = 20:1) in the presence of HA (10 µg/ml). Cytoplasmic and nuclear RNA were 
isolated at different time intervals, as indicated. Real-time PCR was performed to detect the 
presence of IL-10 pre-mRNA (solid line, left axis) and IL-10 mRNA (dash line, right axis). B and 
C, Macrophages were pretreated with U0126 (2 µM) (white circles) or drug vehicle (black 
circles) for 1 h and then infected with lesion-derived amastigotes (Fp. Amastigotes) (at an MOI of 
20:1) plus HA (10 µg/ml) for indicated times. Cytoplasmic and nuclear RNA were isolated, and 
the real-time PCR was performed to analyze the presence of IL-10 pre-mRNA (B) and mature IL-
10 mRNA (C).  
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resulted in histone H3 phosphorylation (Lucas et al., 2005). The nucleosome 2, as 
numbered from the transcriptional initiation site, contains the binding site for the 
transcription factor Sp1, which is important for IL-10 gene expression (Brightbill et al., 
2000; Zhang et al. 2006). The nucleosome 11 is the control that is located about 1000bp 
upstream from the Sp1 binding site. 45 mins post-infection the footpad-derived 
amastigotes along with HA caused histone H3 phosphorylation at Ser 10 on nucleosome 
2 but not distal nucleosome 11 (Figure 14A). There was a rapid binding of Sp1 to IL-10 
promoter correlated with histone phosphorylation at nucleosome 2, but not nucleosome 
11 (Figure 14B). PD98059 completely blocked both histone H3 phosphorylation and Sp1 
binding. 
            In summary, opsonized parasites along with HA activate MAPK/ERK. 
MAPK/ERK activation resulted in histone H3 serine-10 phosphorylation, which leads to 
chromatin remodeling. This remodeling allows the transcription factor Sp1 to gain access 
to its binding element in the IL-10 promoter and drive IL-10 gene expression. 
Manipulating MAPK/ERK Activation in the Macrophages Diminishes the Severity of L. 
Amazonensis Infection  
            Modulating IL-10 levels during Leishmania infections can influence the course of 
disease progression in the host. The over-production of IL-10 can impair the immune 
response to many pathogens as shown in a variety of animal models of infection. In 
contrast, reducing IL-10 often improved the resistance of the host to infection (Kane and 
Mosser, 2001). When rIL-10 was administrated, mice were found to be more susceptible 





Figure 14. IL-10 gene expression requires MAPK/ERK-mediated histone H3 Ser10 
phosphorylation and the recruitment of Sp1. Macrophages (4 x 106 cells) were pretreated with 
or without PD098059 (10 µM) (PD) for 1 h and then infected with or without Fp. amastigote  
(Fp. Am.) plus HA (10 µg/ml) for 45 min. The chromatin fragments were immunoprecipitated 
using a specific Ab against phosphorylated histone H3 at Ser10 (A) or an Ab to Sp1 (B). Real-time 
PCR was performed to determine the presence of DNA associated with nucleosome 2 (black bars) 




albicans, and Trypanosoma cruzi (Redpath et al., 2001). However, if IL-10 levels are 
reduced during infection, mice are more resistant to the intracellular pathogens listed 
previously, as well as T. gondii and L. major. Our previous studies indicated that IL-10 
contributes to leishmaniasis. IL-10 knockout mice are resistant to infection (Kane and 
Mosser, 2001). Because our in vitro studies show that MAPK/ERK activation led to the 
induction of IL-10 production by macrophages, we next performed in vivo experiments to 
determine whether manipulating MAPK/ERK can affect L.amazonensis infection in 
BALB/c mice.  
            BALB/c mice were infected with 105 lesion-derived amastigotes in the right hind 
footpad. Lesion progression was monitored twice weekly over a 7-wk period. The 
MAPK/ERK inhibitor, U0126 (10 mg/kg), was administrated intraperitoneally every 7-
days beginning at the 18th day after infection for 5 weeks (Figure 15A). We selected 
U0126 over PD98059 for these in vivo studies because it has higher potency and 
solubility. Control BALB/c littermates developed measurable lesions within 3 weeks of 
infection and these lesions became progressively larger until the experiment was 
terminated by day 49. The lesions of U0126 treated mice were significantly smaller 
throughout the observation period (p<0.05) after administration of the inhibitor (Figure 
15A). By using both serial dilution assay (left) and qRT-PCR (right) to amplify arasite 
DNA, the parasite burdens in the mice that received U0126 treatment were significantly 
lower than the untreated mice at day 49 (Figure 15B). After challenge with 50 µg/ml 
soluble L. amazonensis antigen (SLA), T cells of lymph nodes obtained from either 
control mice or U0126 treated mice produced the same amount of either IL-4 or IFN-γ, 
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Figure 15. Inhibition of MAPK/ERK activation delays the progression of lesions in mice 
infected with LA in vivo. BALB/c mice control group (n = 6) (circles) and U0126-treated group 
(n = 6) (triangles) were injected with 1 x 105 lesion-derived amastigotes of LA in the hind 
footpad. After 18 days, weekly injections of U0126 (10 mg/kg) were administered 
intraperitoneally for 5 wk. The control group received the same volume of drug vehicle. A, Lesion 
size was measured on the indicated days. B, Parasite burdens in infected footpad were determined 
by limiting dilution assay (left) and qRT-PCR (right), as described in Materials and Methods. 
One representative experiment of three is shown. Data represent mean ± SD. The p values were 
determined by Student’s t test. *, p < 0.05. 
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indicating that the inhibition of MAPK/ERK activation did not skew Th response, i.e., 
Th1 vs. Th2.  
             To determine the correlation between the changes in lesion size and local IL-10 
levels, mice were infected on day 1 with L. amazonensis and administered U0126 
intraperitoneally at weekly intervals thereafter as indicated. At week 4, 5 and 6, mice 
were euthanized, and IL-10 mRNA in the feet of infected mice treated with U0126 
(Figure 16, left, stripped bars) were substantially reduced relative to untreated mice 
(Figure 16, left, open bars). Interestingly, there was no significant differenc  in IL-10 
levels in lymph nodes (Figure 16, right), indicating that IL-10 production in the infected 
footpad itself was responsible for lesion progression. 
Previous studies showed that administration of anti-parasite serum to IgG-
deficient JH BALB/c mice exacerbated L. major infection (Miles et al., 2005). To further 
verify the inhibitory effects of U0126, the same experiments were conducted on IgG-
deficient JH BALB/c mice with L. amazonensis infection. JH mice were infected with 1 x 
104 lesion-derived LA amastigotes (low dose) in the right hind footpad. Started from the 
20th day post-infection, one group of mice was administrated U0126 (10 mg/kg) 
intraperitoneally once per week until 48 days post-infection. At the 21st day, the two 
groups of mice were injected intraperitoneally with 200 µl of anti-LA serum. Lesions in 
JH mice became larger after being injected with anti-LA serum (Figure 17A, open 
triangles). The administration of U0126 reduced the antibody-induced increase in leion 





Figure 16. MAPK/ERK inhibition by U0126 reduces IL-10 gene expression in lesions. 
BALB/c mice were infected with 1 x 105 lesion-derived amastigotes in the right hind footpad. 
Weekly injection of U0126 (10 mg/kg) was administrated to one group intraperitoneally for 6 wk 
( ; n = 3). Total RNA was isolated on the day after U0126 administration for 3 wk, as indicated 
in the figures. IL-10 mRNA levels were determined by qRT-PCR, as described in Materials and 
Methods. After normalization by HPRT mRNA levels, IL-10 mRNA levels of infected mice 
without U0126 treatment (; n = 3) were arbitrarily set as 100%. Relative IL-10 mRNA 
expression in the footpad (left) and the lymph node (right) was determined. Data represent mean 
± SD with triplicates. The p values were determined by Student’s t test. *, p < 0.05. 
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those in mice that didn’t receive antibody (Figure 17A, closed circles). Parasites burdens 
in the infected footpads were measured by qRT-PCR (Figure 17B, left) and limiting 
dilution assay (Figure 17B, right). Mice that were administered anti-LA serum had 
significantly more parasites than untreated mice (p≤0.01) (black bars). The co-
administration of U0126, however, reduced the parasite burdens back to untreated levels 
(stripped bars). Similar studies were also performed using high dose parasites (1×106), 
and they yielded similar results. U0126 treatment can decrease IgG-mediated increase of 
lesion (Figure 17C) that is correlated with reduced parasite burden (Figure 17D). These in 
vivo results are consistent with our in vitro data, showing that MAPK/ERK inhibition 
prevents IgG-mediated disease exacerbation.   
            Taken together, these in vivo observations are consistent with our in vitro data 
showing the MAPK/ERK activation is one of the critical events for parasite-immune 
complex-mediated leishmaniasis progression. The administration of MAPK/ERK 
inhibitors exhibited a significant influence on disease progression, decreasing lesion size 
and reducing parasite burdens. This administration also resulted in reduced IL-10 levels 
in the lesions, but not in the draining lymph nodes, suggesting that localized 
MAPK/ERK-dependent production of IL-10 in the lesions was responsible for lesion 
progression. Thus, pharmaceutical intervention via blocking MAPK/ERK activation 
together with other available therapeutics may provide a novel approach to the treatm nt 
of progressive visceral leishmaniasis. However MAPK’s activation is not only required 
for IL-10 production but may also be required for macrophage microbicidal activity, such 
as NO production. Thus, lesion development in leishmaniasis may represent a balance 
between the immune activating and the immune inhibitory effects of the MAPKs. 
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Figure 17. The inhibition of MAPK/ERK activation prevents IgG-mediated exacerbation of 
disease. JH mice on the BALB/c background were infected with 1 x 10
4 (A and B) or 1 x 106 (C 
and D) lesion-derived amastigotes in the right hind footpad. Two groups of mice (n = 6) were 
injected intraperitoneally with 200 µl of anti-LA serum at the 21st day post-infection. One of 
these groups () was administrated with U0126 (10 mg/kg) intraperitoneally, as indicated. 
Another group of mice (•) (n = 6) was treated with drug vehicle as a control. Lesion size was 
measured on the indicated days following infection with 1 x 104 (A) or 1 x 106 (C) parasites. B, 
Parasite burdens were determined by limiting dilution assay (right) and qRT-PCR (left, and D), as 
described in Materials and Methods. Data represent mean ± SD. The p values were determined by 





            The interaction of Leishmania parasites with host macrophages can result in 
altered intracellular signaling pathways, leading to parasite survival within infected 
macrophages. In this study, we describe the activation of MAPK, MAPK/ERK following 
infection of macrophages with LA parasites. Previous studies have correlated 
MAPK/ERK activation with leishmaniasis. Lipophosphoglycan from Leishmania has 
been reported to subvert macrophage IL-12 production by activating MAPK/ERK (Feng 
et al., 1999). It has also been suggested that the strength of CD40 signaling may influence 
the specific MAPK pathway that is activated, and thereby influence cytokine production 
from infected cells (Mathur et al., 2004). In the present work, we demonstrate that 
opsonized amastigotes of Leishmania induce MAPK-MAPK/ERK activation in 
macrophages. This activation results in epigenetic modifications of il-10 gene locus, 
thereby causing a superinduction of IL-10 from infected macrophages.  
            Importantly, lesion-derived amastigotes alone are not sufficient to induce IL-10 
production, despite their ability to rapidly activate MAPK/ERK. Parasites must be 
combined with some inflammatory stimulus to induce macrophage IL-10 production. 
These stimuli can be fragments of hyaluronan, called LMW-HA. Hyaluronan is a major 
component of extracellular matrix and exists as a high-molecular weight polymer under 
normal physiological conditions. After tissue injury, small fragments of hyaluronan are 
generated at the site of injury (Termeer et al., 2002; Jiang et. al., 2005). Several studies 
suggest that these hyaluronan fragments can signal through TLR2 and 4 on endothelial 
cells and DCs (Hodge-Dufour et al., 1997; Termeer et al., 2002; Jiang et. al., 2005). 
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LMW-HA is not the only inflammatory signal that can co-induce IL-10 production. Often 
leishmanial lesions are super-infected with other microorganisms, which can provide the 
inflammatory stimulus via any TLR, including TLR2 or 4. Alternatively, the lysis of 
heavily infected macrophages may release heat shock proteins (Tsan and Gao, 2004) or 
high mobility group protein 1 (Park et al., 2004) from mammalian cells to stimulate IL-10 
production.  
            Our findings also indicate that signaling through the macrophage FcγR is critical 
for IL-10 induction. Axenically grown amastigotes that lack IgG (Kane and Mosser, 2001) 
failed to activate MAPK/ERK and failed to induce IL-10 production (Figure 6). The 
opsonization of these organisms with IgG restored their ability to activate MAPK/ERK 
and induce IL-10 (Figure 8B). Furthermore, cells lacking FcR γ chains failed to activate 
MAPK/ERK, and they failed to produce IL-10 in response to infection (Figure 10) (Kane 
and Mosser, 2001).  
            In our model, the delayed activation of MAPK/ERK by inflammatory mediators, 
such as LMW-HA, is sufficient to induce only modest l vels of IL-10 production from 
macrophages. However, the addition of IgG-opsonized amastigotes dramatically 
increased the speed with which MAPK/ERK was activated, and it also increased the 
magnitude and the duration of MAPK/ERK activation. This hyperactivation of 
MAPK/ERK resulted in the phosphorylation of histone H3 at Ser10. The histones 
associated with Sp1 binding site were highly phosphorylated. The phosphorylation of 
histones makes this promoter region more accessible to Sp1 (Figure 14B), resulting in a 
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dramatic superinduction of IL-10 transcription. The result is the secretion of high levels 
of this inhibitory cytokine by infected macrophages.  
            A critical component of the proposed model is that the amastigotes in th  lesions 
have host IgG on their surface, which has been reported before (Guy and Belosevic, 
1993; Peters et al., 1995; Kane and Mosser, 2001). The IgG on amastigotes appears to be 
the result of a parasite-specific IgG response by the host. Several studies hav  
demonstrated that high levels of parasite-specific IgG are generated during leishmaniasis 
(Kima et al., 2000; Colmenares et al., 2002). This is especially true with human visceral 
leishmaniasis in which rheumatoid factor (Carvalho et al., 1983; Newkirk, 2000; Pearson 
et al., 1983) and parasite-specific IgG levels are high (Junqueira et al., 2003; Ghosh et 
al., 1995; Casato et al., 1999; Jeronimo et al., 2000; Galvão-Castro et al., 1984; Elassad 
et al., 1994), making it more likely that amastigotes d rived from lesions would be 
opsonized with host IgG. Our model would predict that disease exacerbation caused by 
immune complexes would only occur late in disease, after parasite-specific IgG was 
generated. We predict that the re-infection of macrophages by IgG-opsonized amastigotes 
would be the trigger for IL-10 production. For these reasons, we performed in vivo 
infection studies in which we inhibited MEK/MAPK/ERK activation relatively late in 
disease, after the lesions had progressed for 21 days. The administration of MAPK/ERK 
inhibitors at this late time still exhibited a significant influence on disease progression, 
decreasing lesion size and reducing parasite burdens. This administration also resulted in 
reduced IL-10 levels in the lesions, but not in the draining lymph nodes, suggesting that 
localized MAPK/ERK-dependent production of IL-10 in the lesions was responsible for 
lesion progression.  
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In summary, our current findings detail the molecular mechanisms of IL-10 
production by amastigote-infected macrophages. They reveal a central role for 
MAPK/ERK that is required for maximal IL-10 production. These studies lead to several 
predictions. The first is that the activation of MAPK/ERK in any infectious disease may 
predispose the host to inhibitory IL-10 production. These studies confirm a role for IL-10 
during disease progression, and they may lead to the development of a new class of 
therapeutics to treat human visceral leishmaniasis. Finally, these studies would predict 
that vaccines against intracellular pathogens might be more effective if administered in 
the presence of an MAPK/ERK inhibitor. Vaccination strategies that inhibit regulatory 
signaling networks in DCs by encompassing MAPK/ERK inhibitors as nanoparticles or 
encapsulating other regulatory proteins together with TLR ligands and relevant antigen 




CHAPTER 4: THE ROLE OF MAPK/p38 IN IL-12 PRODUCTION IN 
CLASSICALLY ACTIVATED MACROPHAGES 
            Classically activated macrophages, which are activated by TLR ligands, play an 
important role in parasite killing by producing NO and proinflammatory cytokines, 
TNFα and IL-12. TLRs can trigger innate immune responses through MAPKs signaling 
pathways. It appears that MAPK/p38 activation may play a dominant role in TLR4-
mediated signaling. It has been shown that the MAPK, MAPK/p38, plays a positive role 
in TNFα production (Mahtani et al., 2001). Evidence of MAPKs involved in IL-12 and 
IL-23 production has been reported, but due to different cell types and varied 
experimental conditions, these results are contradictory. Thus, how MAPKs affect IL-
12p40 and IL-12p70 remains elusive.  
 MAPK/p38 Inhibition Has Reciprocal Effects on IL-12 and TNFα       
            MAPK/p38 inhibitors were employed to determine whether MAPK/p38 could 
influence macrophage IL-12p40 production. LPS induced the production of both TNFα 
and IL-12p40 from bone marrow derived macrophages (Figure 18A). Inhibition of 
MAPK/p38 by SB203580 reduced TNFα but increased IL-12p40 in a dose-dependent 
manner (Figure 18A). At the highest levels of MAPK/p38 inhibitor used, IL-12p40 level 
was increased by approximately 5-fold. It has been previously reported that SB203580 
can inhibit TNFα production (Mahtani et al., 2001), but the enhancement of IL-12p40 
was not expected. Next MAPK/p38 activation was examined in BMMφ using western 





Figure 18. MAPK/p38 inhibition has reciprocal effects on IL-12 and TNFα. A, Macrophages 
(3 x 105 cells) were pretreated with increasing concentrations of SB203580 for 1 h and t en 
stimulated with LPS (10 ng/ml) for overnight. Supernatants were harvested, and IL-12p40 and 
TNFα production were determined by ELISA. Values are representative of at least hree 
independent experiments (mean ± SD of triplicates). B, Macrophages (2 x 106 cells) were 
pretreated with SB203580 (5 µM) for 1 h. Cells were then stimulated with LPS (10 ng/ml) for 0, 
10, 20, 30, 60 and 90mins. Cell lysates were prepared for Western blotting analysis to detect 
phosphorylated MAPK/p38, phosphorylated MAPKAPK-2 and total MAPK/p38 protein. 
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LPS in a time-dependent manner (Figure 18B). Both MAPK/p38 and its downstream 
kinase MAPKAPK-2 activation could be detected as early as 20 min after stimulation. 
Activation reached a peak at 30 mins and persisted for 90 mins. SB203580 inhibits the 
enzymatic activity of MAPK/p38. Thus, treatment of macrophages with 5 µM SB203580 
blocked the phosphorylation of its downstream MAPKAPK-2 without affecting 
MAPK/p38 phosphorylation (Figure 18B). 
MAPK/p38 Inhibition Has the Similar Effects on Cytokine Production Mediated by 
Different TLR Agonists 
            In order to test whether MAPK/p38 inhibition-induced IL-12p40 production is a 
unique feature for TLR4 stimulation or common to all TLR activation, CpG, a ligand for 
TLR9, lipoprotein A, a ligand for TLR2/TLR6, and flagellin, a ligand for TLR5 were 
used to stimulate macrophages. All of these TLR agonists induced TNFα and IL-12p40 
production from macrophages (Figure 19). SB203580 showed similar effects on cytokine 
production as it did for LPS stimulation.   TNFα was reduced while IL-12p40 was 
increased in a dose-dependent manner (Figure 19). The total amount of cytokine induced 
by these different TLR agonists varied, but the extent of MAPK/p38-mediated cytokine 
enhancement and inhibition was comparable. These data indicate that MAPK/p38 
inhibition-induced IL-12p40 production was a universal feature for TLR-mediated 
signaling pathways. 
Similar Roles of MAPK/p38 on Cytokine Production in Different APCs 





Figure 19. MAPK/p38 inhibition has the similar effects on cytokine production mediated by 
different TLR agonists. Macrophages (3 x 105 cells) pretreated with increasing concentrations of 
SB203580 for 1 h were stimulated with CpG (10 ng/ml), lipoprotein A (5µg/ml) and flagellin 
(1µg/ml) for overnight. Supernatants were harvested to detect IL-12p40 and TNFα production 
using ELISA. Data represent one of three independent experiments (mean ± SD of triplicates). 
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experiments were carried out using resident peritoneal macrophages and BMDCs in 
addition to BMMφs. In the presence of LPS, SB203580 induced IL-12p40 production 
from all three types of cells, BMMφs, peritoneal resident macrophages and BMDC 
(Figure 20). In BMDCs, MAPK/p38 inhibition also enhanced IL-12p70 production by 
LPS (Figure 20). A structurally related control compound, designated SB202474, had no 
effect on IL-12p40 and IL-12p70 production. For all of these studies, the structural 
control compound SB202474 failed to influence cytokine production.  
            These data show a similar degree of IL-12 enhancement by inhibition of 
MAPK/p38 with different TLR agonists not only in BMMφ but also in peritoneal resident 
macrophages and BMDCs. Thus, the MAPK/p38 pathway plays a negative regulatory 
role in IL-12 production by antigen-presenting cells. 
MAPK/p38 Inhibition Increases IL-12p40 Due to Enhanced mRNA Stability 
            To gain further insight into the molecular mechanisms of IL-12p40 gene 
expression by MAPK/p38, nuclear pre-mRNA and cytoplasmic mature mRNA were 
isolated following stimulation of macrophages with LPS. Gene transcription was 
monitored by measuring pre-mRNA formation using real-time PCR as previously 
described (Zhang et al., 2006). The accumulation of cytoplasmic mature spliced IL-12 
mRNA was also examined. IL-12p40 pre-mRNA expression quickly reached maximal 
levels at 1 hour after LPS stimulation and returned to basal levels by 4 hours (Figure 21A, 
solid line). IL-12p40 mature mRNA-induced by LPS also peaked at around 1 hour and 
returned to basal level between 4 to 6 hours (Figure 21B, solid line). Interestingly, 




Figure 20. Similar roles of MAPK/p38 on cytokine production from BMMφs, peritoneal 
resident macrophages and BMDCs. BMMφs (top panel), peritoneal resident macrophages 
(middle panel) and BMDCs (bottom panel) (3 x 105 cells) were pretreated with increasing 
concentrations of SB203580 (red circle) and SB202474 (white circle) for 1 h and then stimulated 
with LPS (10 ng/ml) for overnight. Supernatants were harvested for ELISA analysis of IL-12p40 






Figure 21. MAPK/p38 inhibition enhances IL-12p40 mRNA accumulation. A, Macrophages 
(4 x 106 cells) were pretreated with (dash line) or without (solid line) SB203580 (5 µM) and then 
stimulated with LPS (10 ng/ml). Cytoplasmic and nuclear RNA were isolated at different time 
intervals as indicated. Real-time PCR was performed to detect the pres nce of IL-12p40 pre-
mRNA (A) and IL-12p40 mRNA (B). 
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line) but enhanced mature mRNA formation (Figure 21B, dash line).  
            In order to verify the effect of MAPK/p38 inhibition on IL-12p40 promoter 
activity, RAW264.7 cells were transfected with pGL3-IL-12p40-promoter plasmid and 
pRL-TK plasmid (as an internal control) to normalize for transfection and harvest 
efficiency. After 24 hrs, cells were pretreated for 1 hour with drug vehicle (control) or 
SB203580, then stimulated with LPS. SB203580 can inhibit IL-12p40 promoter activity 
(Figure 22), which is correlated with the results shown in Figure 21A that MAPK/p38 
inhibition inhibited IL-12p40 transcripts. 
Since IL-12p70 is a heterodimeric cytokine comprising p35 and p40, the changes 
of IL-12p35 mRNA were measured in both BMMφ (Figure 23A) and BMDC (Figure 
23B). Inhibition of MAPK/p38 activation by SB203580 did not have a significant effect 
on IL-12p35 mRNA as compared to IL-12p40 mRNA.  
            As MAPK/p38 inhibition had a positive effect on IL-12p40 mRNA accumulation 
but not on transcription, therefore IL-12p40 mRNA degradation was further studied in 
more details. Macrophages treated with SB203580 or its drug vehicle was stimulated 
with LPS for 2 hours, and then a transcription inhibitor actinomycin D (10 µg/ml) was 
added. Degradation of mRNA was measured at different time points for the following 4 
hours. As shown in Figure 24, in the presence of SB203580 IL-12p40 mRNA (top panel) 
was more stable with its half-life increased by approximately two-fold, rom 1.1 hours to 
2.5 hours. In contrast, both TNFα (middle panel) and IL-10 (bottom panel) mRNA were 





Figure 22. IL-12p40 promoter activity is down-regulated by MAPK/p38 inhibitor. 
RAW264.7 macrophage cells were transfected with pGL3-IL-12p40-promoter plasmid nd pRL-
TK plasmid as internal control to normalize for transfection and harvest efficiency. After 24 hrs, 
cells were pretreated 1 hour with drug vehicle (control) or 5µM SB203580, and then stimulated 
with LPS (10 ng/mL). IL-12p40 promoter activity is expressed as the ratio of firefly luciferase 





Figure 23. MAPK/p38 inhibition has no significant effect on IL-12p35 mRNA. BMMφ (A) or 
BMDC (B) were pretreated without (circle and dash line) or with (triangle and solid line) 
SB203580 (5 µM) and then stimulated with LPS (10 ng/ml). Cytoplasmic RNA was isol ted at 






Figure 24. MAPK/p38 inhibition affects the mRNA stability of cytokines. Macrophages 
pretreated with drug vehicle (solid line) or SB203580 (5 µM) (dash line) for 1 h were stimulated 
with LPS (10 ng/ml) for 2 hours and then actinomycine D (10µg/ml) was added. RNA was 
isolated at the indicated time intervals. qRT-PCR was performed to analyze the mRNA levels of 
cytokines (top: IL-12p40, middle: TNFα, and bottom: IL-10) and GAPDH. Relative levels of 
each cytokine are normalized with GAPDH as described in Materials and Methods. The 
normalized mRNA levels in arbiturary units are presented on a log scale to obtain a linear 
relationship. Data represent one of three independent experiments (mean ± SD of triplicates).  
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two-fold, from 1.1 hours to 0.4 hours, which is in agreement with previous findings 
(Mahtani et al., 2001). These data indicate that the increased IL-12p40 production 
mediated by MAPK/p38 inhibition is at least in part attributed to enhanced mRNA 
stability. 
The Effect of MAPK/p38 on IL-12p40 Can be Independent of IL-10   
            It is well know that IL-10 can inhibit IL-12 transcription and translation (Mosser 
and Zhang, 2008). Therefore macrophages derived from IL-10 knockout mice were used 
to determine whether IL-12 enhancement caused by MAPK/p38 inhibition was dependent 
on IL-10 changes. MAPK/p38 inhibition by SB203580 increased IL-12p40 production by 
about three-fold in IL-10-/- macrophages (Figure 25A), while TNFα production was 
significantly reduced by SB203580 (Figure 25B). This increase occurred despite the fact 
that basal LPS-induced IL-12 production was much higher in IL-10-/- macrophages as 
compared to the cells derived from control littermates. Similar to what had been o s rved 
in macrophages derived from wild type mice, MAPK/p38 inhibition diminished early IL-
12p40 transcription induced by LPS but increased mature mRNA accumulation in IL-10 
deficient macrophages (Figure 26) due to increase in mRNA stability. LPS-induced IL-
12p40 mRNA was more stable in the presence of SB203580 (Figure 27A) whereas TNFα 
mRNA became less stable (Figure 27B). These data indicate that MAPK/p38 inhibition 
induced enhancement of IL-12 production can occur in the absence of IL-10.  





Figure 25. The effect of MAPK/p38 on IL-12 can be independent of IL-10.  IL-10-/- 
macrophages were pretreated with increasing concentrations of SB203580 (solid line) or 
SB202474 (dash line) for 1 hour and then stimulated with LPS (10 ng/ml) for overnight. 
Supernatants were harvested, and IL-12p40 (A) and TNFα (B) production were determined using 





Figure 26. MAPK/p38 inhibition induced IL-12p40 mRNA accumulation is independent of 
IL-10. A, IL-10-/- macrophages (4 x 106 cells) were pretreated with (dash line) or without (solid 
line) SB203580 (5 µM) and then stimulated with LPS (10 ng/ml). Cytoplasmic and nuclear RNA 
were isolated at different time intervals as indicated. Real-time PCR was performed to detect the 





Figure 27. Regulation of cytokines mRNA stability by MAPK/p38 inhibition is IL-10 
independent. IL-10-/- macrophages were pretreated with SB203580 (solid line) or with 
SB202474 (dash line) (5 µM) for 1 h were stimulated with LPS (10 ng/ml) for 2 hours and then 
actinomycin D (10µg/ml) was added. RNA was isolated afterwards at the indicated time intervals. 
qRT-PCR was performed to analyze the mRNA stability of cytokines (A, IL-12p40, and B, 




Four isoforms of MAPK/p38, α, β, γ and δ, have been identified. Western blot 
analysis could only detect the presence of the α form but not the other three isoforms in 
the BMMφs (Figure 28A, inserted), and real-time PCR analysis showed that MAPK/p38α 
was the dominant form, exceeding MAPK/p38β levels by approximately 10-fold (Figure 
28A). MAPK/p38δ and γ mRNA expression was barely measurable (Figure 28A). To 
further examine the specific role for MAPK/p38 in IL-12 induction, siRNA specific for 
MAPK/p38α were introduced into BMMφs 48 hours before cells were stimulated with 
LPS. As shown in Figure 26B, 10 nM of siRNA specific for MAPK/p38α were sufficient 
to knock down 80% of MAPK/p38α mRNA expression as measured by real-time PCR 
and more than 60% of its protein level as confirmed by western blot analysis. Knock-
down of MAPK/p38 in primary macrophages enabled these cells to produce more IL-
12p40. This increase in p40 production correlated with the dose of siRNA used, and at 
the concentration of 30 nM, p40 production approached the levels observed with 
SB203580 inhibition (Figure 28C). The data further confirm that MAPK/p38 is the target 
for its role on IL-12p40 production and down-regulation of MAPK/p38 activity increases 
LPS-induced IL-12p40 production. 
MKK3 Plays the Same Role on LPS-induced IL-12 Production in Macrophages 
            MKK3 is one of the upstream kinases that directly activate MAPK/p38. In order 
to show a role of MAPK/p38, macrophages from the MKK3 knockout mice were 
employed. In the wild type macrophages, LPS induced phosphorylation of both 




Figure 28. MAPK/p38 knock down has the same effect on IL-12p40. A, Expression of 
MAPK/p38 isoforms in BMMφs. qRT-PCR was performed to detect the presence of 
MAPK/p38α, β, γ and δ mRNA. (Insertion) Cell lysates from macrophages were prepared for 
western blotting analysis of protein MAPK/p38α, β, γ or δ and MAPK/ERK. B, 10nM siRNA or 
mock siRNA was transfected into BMMφs by nucleofection. BMMφs were cultured for 48 hours. 
Total RNA was isolated and qRT-PCR was performed to analyze MAPK/p38α mRNA. 
(Insertion) Cell lysates from siRNA-transfected macrophages were prepared for western blotting 
analysis of protein MAPK/p38α or MAPK/ERK. C, BMMφs were transfected with mock siRNA 
(30 nM) for 48 hours, and then treated with or without SB203580 (5 µM) for 1 hour before LPS 
stimulation for overnight; or BMMφs were transfected with 3nM, 10nM and 30nM siRNA 
targeting MAPK/p38 for 48 hours, and then stimulated with LPS for overnight. Supernatants 





Figure 29. The role of MKK3 on cytokine production. A, BMMφs from MKK3 knocked out 
mice and control littermates were stimulated with LPS (10ng/ml) for the indicated time interval. 
Cell lysates were prepared for western blotting analysis of phospho-MAPK/p38, phospho-MK2 
and phospho-MAPK/ERK as well as β–actin. B, BMMφs from wild type mice (black bars) and 
MKK3 knocked out mice (white bars) were primed with or without IFNγ (100U/ml) and then 




MKK3 -/- cells, the extent of LPS-induced MAPK/p38 and MK2 activation was markedly 
reduced (Figure 29A). In the absence of MKK3, these stimulated macrophages were 
capable of producing substantial amounts of IL-12p40 upon LPS stimulation (Figure 29B, 
left panel). Furthermore, when these macrophages were primed with IFN-γ (100U/ml) 
overnight and then stimulated, MKK3-/- macrophages produced more IL-12p40 (Figure 
29B, middle panel) and IL-12p70 (Figure 29B, right panel) than wild type macrophages 
upon LPS stimulation. These data demonstrate again that MAPK/p38 plays a negative 
role on LPS-induced IL-12 production. 
Inhibition of MAPK/p38 Activation Favors a Th1 Immune Response 
            Since MAPK/p38 inhibition could increase IL-12 production in vitro, we 
investigated whether MAPK/p38 inhibition could polarize Th1 immune response. CpG is 
a well-defined vaccine adjuvant for years. Macrophages were stimulated with OVA with 
or without CpG plus SB203580. OVA itself barely induced IL-12 production (Figure 
30A). Addition of CpG induced some IL-12p40 (Figure 30A, white bar) and a measurable 
level of IL-12p70 (Figure 30A, gray bar). Inhibition of MAPK/p38 activation by 
SB203580 strongly facilitated CpG to induce much more IL-12p40 and IL-12p70 (Figure 
30A). T cells derived from D011.10 mice, expressing transgenic TCRs specific for OVA 
peptides, were co-cultured with those treated macrophages for 3 days, and the 
supernatants were collected for detection of IFN-γ and IL-4. These T cells produced more 
IFN-γ and less IL-4 in the presence of macrophages that were pre-treated with OVA plus 







Figure 30. Inhibition of MAPK/p38 activation favors Th1 responses in vitro. A, BMMφs were 
stimulated with OVA (100µg/ml), OVA+ CpG (10ng/ml) with or without SB 203580 (5µM) for 
overnight. Supernatant were collected to detect IL-12p40 and IL-12p70. B, The remaining treated 
BMMφs were co-cultured with or without D011.10 T cells for 3 days. Supernatants were 
harvested to detect IFNγ and IL-4 production using ELISA. 
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To examine whether the inhibition of MAPK/p38 would improve vaccinations 
against leishmaniasis, whose healing is linked to Th1 immunity, heat-killed L. major 
(HKLM) with or without CpG and SB203580 were administrated to BALB/c mice in the 
left hind footpad. One week later the mice were boosted again. Then the mice were 
infected with promastigotes in the right hind footpad. Lesion progression was monitored 
weekly over an 8-wk period. As shown in Figure 31A, control BALB/c mice, or mice 
vaccinated with HKLM along with control CpG developed measurable lesions within 5 
weeks of infection, and these lesions became progressively larger until the experiment 
was terminated on week 8. Lesions in mice vaccinated with HKLM plus a low amount 
(0.5 µg) of CpG were significantly smaller after 5 weeks of infection. The addition of 
SB203580 to the CpG/HKLM vaccine resulted in a further reduction in lesion size.  
Parasite burdens in the infected feet were measured by limiting dilution. SB treated mice 
had fewer parasites that correlated with smaller lesions (Figure 31B). Cytokine 
production was measured from the supernatant obtained from the lymphocytes derived 
from lymph nodes from these mice. Production of more IFN-γ accompanied by less IL-4 
was observed in SB treated group (Figure 31C). Thus, inhibition of MAPK/p38 can 






Figure 31. Inhibition of MAPK/p38 activation polarizes Th1 responses and enhances CpG 
adjuvant effect to protect leishmaniasis in vivo. A, BALB/c female mice were injected with 
PBS (black closed circle) or heat-killed L. major (50 µg) with or without CpG (0.5 or 2 µg/ml) 
and SB203580 (20µM) on their left footpad as indicated in the figure on day 0 and day 7. On day 
30, mice were challenged with 1× 05 L. major metacyclic promastigotes on their right footpad. 
Footpad lesions were monitored on the indicated days. B, Parasite burdens in infected footpad 
were determined by limiting dilution assay as described in Materials and Methods. One 
representative experiment of three is shown. C, Cytokine production by lymph node T cells from 
infected mice. Lymph nodes were removed on day 56 and stimulated with anti-CD3 and anti-
CD28 for 48 hours. Then the cells were stimulated with PMA for 5 hours. Supernatants were 
harvested and assayed for IFN-γ and IL-4 by ELISA. Data represent mean ± SD. The p values 
were determined by Student’s  test. The symbol of * represents p < 0.05. 




            In this portion of the dissertation, we provide evidence to support the notion that 
manipulation of the MAPKs can result in profound alterations in cytokine production and 
bias a developing immune response. Specifically, we show that the inhibition of 
MAPK/p38 activation can induce the hyper-production of IL-12 by stimulated 
macrophages or DCs, which can polarize host immunity towards a Th1 response. We 
utilized several different experimental approaches to manipulate MAPK/p38 activity and 
increase in IL-12 production. MAPK/p38 inhibitor, SB203580, was used. It enhanced IL-
12 production and reduced the production of TNFα in a dose-dependent manner. Knock-
down of MAPK/p38 by specific siRNAs also resulted in increased IL-12 production, and 
macrophages taken from mice with a targeted deletion of the upstream kinases MKK3 
had a similar effect on IL-12 and TNFα production. We demonstrated that APCs pre-
treated with MAPK/p38 inhibitors skewed antigen-specific T cells to produce morIFN-γ 
and less IL-4. Finally, MAPK/p38 inhibitor enhanced the efficacy of CpG plus HKLM 
vaccination against leishmaniasis. Thus, this work suggests that MAPK/p38 inhibitor 
may be applied as adjuvants to improve vaccinations against intracellular pathogens.    
Previous studies have indicated that MAPK/p38 can promote inflammation by 
targeting NF-κB to the promoters of inflammatory genes (Saccani et al., 2002) and by 
stabilizing inflammatory gene transcripts (Mahtani et al., 2001). However, the role of 
MAPK/p38 activation on IL-12 has remained somewhat controversial. In an early report, 
Salmon et al (Salmon et al., 2001) reported that SB203580 could enhance LPS-initiated 
IL-12 production by peritoneal exudate macrophages. However, in a more recent study, 
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Kang et al (Kang et al., 2008) showed that macrophage deletion of MAPK/p38α had a 
negative effect on IL-12 production. MK2 is the kinase directly downstream of 
MAPK/p38α/β. In MK2-/- macrophages LPS induced more IL-12p40 than the cells of 
control littermates (Kotlyarov and Gaestel, 2002). MKK3 is the dominant upstream 
kinase that controls activation of MAPK/p38 kinases. Lu et al. reported that IL-12 
production was reduced in the “elicited” peritoneal macrophages from MKK3 deficient 
mice (Lu et al., 1999). In our current study, we showed that MAPK/p38 inhibition 
enhanced IL-12p40 production from macrophages and IL-12p70 production from 
dendritic cells. Our results are in agreement with the results from the report of MK2-/- 
macrophages (Kotlyarov and Gaestel, 2002) and a more recent study in which 
plasmodium falciparum glycosylphosphatidylinositols (GPIs) or LPS-induced IL-12p40 
production was enhanced in MK2-/- macrophages or SB203580-treated wild-type 
macrophages (Zhu et al., 2009). 
 MK2 as a major target downstream of MAPK/p38α and plays a key role to 
regulate gene expression either at transcriptional or post-transcriptional level. It has been 
shown that MK2 is essential for LPS-induced regulation of cytokine mRNA stability and 
translation possibly through the modification of mRNA-binding protein by 
phosphorylation (Mahtani et al., 2001). TNFα is one of the cytokines whose mRNA is 
stabilized by the activation of MAPK/p38-MK2 pathway. In the current study, MK2 
activation was inhibited by MAPK/p38 inhibitor, which resulted in the reduction of 
TNFα production and an increase in IL-12p40 production. Our data showed that 
MAPK/p38 inhibition caused a decrease in TNFα mRNA half-life, and a concordant 
increase in the stability of IL-12p40 mRNA. It has been known that TTP is the target of 
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MK2 activation. Phosphorylated TTP binds to the AU-rich region of 3’-mRNA of TNFα 
to prevent its degradation (Sun et al., 2007). How inactivation of MK2 or MAPK/p38 
enhances LPS-induced IL-12p40 gene expression via its mRNA stabilization needs to be 
addressed in future experiments. None of typical AU-rich elements has been definitively 
identified in the 3’-untranslated region of IL-12p40 mRNA, thus, tristetraprolin may not 
function on IL-12p40 mRNA as it does with TNFα or other mRNAs containing AU-rich 
elements. As recently reported by Akira and colleagues, zinc finger CCCH-type 
containing 12A (Zc3h12a) that has been identified as a TLR4 signaling-inducible RNase 
specifically accelerates mRNA degradation of Il6 and other genes including Il12p40 and 
calcitonin receptor (Calcr) (Matsushita et al., 2009). The effect of MAPK/p38-MK2 
pathway on the function of Zc3h12a warrants evaluation in the near future. Microarray 
will provide us more candidate molecules that may be involved in IL-12p40 mRNA 
degradation. MAPK/p38-MK2 pathway can also regulate the targets other than TTP. In 
the study of plasmodium falciparum glycosylphosphatidylinositols-induced IL-12p40 in 
MK2-/- macrophages, the enhanced binding of NF-κB to IL-12p40 promoter region and 
the reduction in the expression of transcription repressors GAP-12 and c-Maf were 
attributed to the increasing IL-12p40 gene expression (Zhu et al., 2009). In our study, IL-
12p40 transcription as determined by measuring pre-spliced mRNA that was moderately 
decreased in the macrophages treated with MAPK/p38 inhibitors. Furthermore, 
MAPK/p38 inhibition reduced IL-12p40 promoter activity as determined by transient 
transfection of IL-12p40 promoter reporter experiments. Bioactive IL-12 is composed of 
equal molar amounts of p40 and p35. It has been known that contrary to expectation, p40 
is induced in as much as 100-fold excess over p35 regardless of stimuli (Trinchieri G. 
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1995; Liu et al., 2004). The current result of which IL-12p35 mRNA level was not 
significantly affected by MAPK/p38 inhibition in both bone marrow derived 
macrophages and DCs suggests that IL-12p40 mRNA is the main target for such 
regulation at mRNA level. However, one could not rule out the possibility of MAPK/p38 
pathway may play a role to regulate IL-12p35 at translational and/or post-translational 
levels, which warrents for future experiments. Taken together, the effect of MAPK/p38 
inhibition on IL-12 regulation is mainly at the post-transcriptional level. In addition to its 
role in mRNA decay, MAPK/p38 and MK2 have also been implicated in controlling 
mRNA translational and protein folding activity (Gaestel, 2006). Thus, it is possible that 
MAPK/p38-MK2 pathway may also control IL-12 production at the translational level. 
            In response to signals from parasite antigens or adjuvants, such as TLR ligands, 
resident immature DCs at the site of infection or vaccination undergo a maturation 
program characterized by enhanced expression of co-stimulatory molecules and 
inflammatory cytokines. These highly stimulated DCs migrate to T cell ar as in the 
draining lymph nodes and present antigens to T cells, which result in increased antign-
MHC complexes, co-stimulatory molecules and pro-inflammatory cytokines. IL-12 and 
IL-18 secreted by DCs induce IFN-γ from T cells and favor robust Th1 immunity. The 
differential development of Th1- versus Th2-type responses in Leishmania-infected mice 
has provided an excellent model for the study of immune regulators that manipulate the in 
vivo immunological development to alter the disease phenotype. The ability to alter Th 
responses in BALB/c mice and to assess the functionality of these responses with a 
biologic correlation has made this a useful model for vaccine development against 
diseases requiring Th1 immunity.  
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 IL-12 functions as a Th1-skewing cytokine to induce IFN-γ, thus, MAPK/p38 
inhibition would be a strategy to modulate the host immunity against certain diseases. 
Indeed, macrophages primed with OVA antigen together with MAPK/p38 inhibitor 
skewed T cells to produce more IFN-γ during secondary stimulation. Thus, in theory 
MAPK/p38 inhibitors such as SB203580 could be used as an adjuvant to boost cell 
mediated immunity and improve vaccines against intracellular pathogens such as 
Leishmania. The efficacy of different anti-leishmania vaccine strategies has been 
experimentally evaluated. Among these strategies, it appears that CpG is an effective 
adjuvant to boost the host immunity against this disease (Rhee et al., 2002). MAPK/p38 
inhibition dramatically enhanced CpG-induced production of both IL-12p40 and IL-
12p70 from macrophages and DCs. CpG has been known to enhance the function of 
APCs. CpG, via TLR9, augments both the activation and maturation of DCs. When 
added along with SB203580 to inhibit MAPK/p38 activation, CpG enhanced IL-12 
production and skewed immunity towards Th1 by producing more IFN-γ (Hemmi et al., 
2000). In our mouse model of L. major infection, vaccination with autoclaved L. major 
parasites plus CpG and SB203580 was able to inhibit disease progression and had a 
higher efficacy than autoclaved L. major parasites plus CpG without SB203580. 
Inhibitors for MAPK/p38 kinase have been considered for clinical applications to 
control inflammation and different generations of MAPK/p38 inhibitors with more potent 
affinity and specificity have been developed such as VX-745 and BIRB-796 by 
pharmaceuticals for clinical applications (Gaestel e  al., 2007). Our data suggests that 
targeting MAPK/p38 activation can not only control unwanted inflammatory response 
such as TNFα overproduction that may have harmful consequences on the host, but also 
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increase IL-12 production that leads to the beneficial immunity against invading 
microorganisms. Thus, it might be possible that administration of the inhibitors specific 
for MAPK/p38-MK2 pathway would be an alternative strategy to effectively vaccin te 




The consequence of events that occur during and after Leishmania invasion can 
be considered as macrophage defects to efficiently kill the parasites. The interaction of 
macrophages receptors with appropriate ligands leads to trigger downstream transductio  
signaling pathways to yield a variety of responses of which is characterized by their 
protective or hazardous role. Macrophages can be activated by both IFN-γ and TLR 
ligands to produce IL-12 that promotes Th1 cell differentiation and induces IFNγ 
production from T cells. IFN-γ in turns activates more macrophages to produce NO to kill 
Leishmania. During the chronic infection stage, host will generate large amounts of anti-
Leishmania IgG that opsonizes parasites. High production of IL-10 initiated by the 
ligation of FcγR by IgG opsonized Leishmania and activation of TLRs plays a hazardous 
role for the host. Our findings reveal the molecular mechanisms of how the MAPKs 
regulate the cytokines production in Leishmania infection. MAPK/p38 inhibition induced 
IL-12p40 hyperinduction is mainly due to enhanced mRNA stability. MAPK/ERK 
activation initiated chromatin modification at the IL-10 locus, which allowed for 
transcription factor Sp1 binding to drive IL-10 expression. The metacyclic L. major 
promastigotes are poor inducers of IL-12 production. In contrast, the procyclic 
promastigotes collected from the logarithmic phase of the culture are capable of inducing 
IL-12 and other cytokines (Sartori et al., 1997). Furthermore, almost every infected 
macrophage lost its capability to produce IL-12 in response to IFN-γ/LPS stimulation. 
Hence, the question remains to be addressed in the future: do metacyclic parasite-infected 
macrophages utilize the same signaling pathway as procyclic parasite-infected 
macrophages to produce cytokines or do they acquire novel mechanisms? IL-12 has been 
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administrated as an adjuvant to vaccination with limited efficacy, possibly due to its 
compensatory induction of IL-10 (Meyaard et al., 1996). Thus, circumventing the 
immunosuppressive effects of IL-10 could enhance the therapeutic efficacy of IL-12 as 
an adjuvant. Therefore, based on our current observations, i.e., down-regulation of IL-10 
by inhibition of MAPK/ERK and enhancement of IL-12 via inhibition of MAPK/p38, the 
combination of both MAPK/ERK and MAPK/p38 inhibitors could be envisaged as a 
novel adjuvant to vaccination in the future. By manipulating the MAPKs may provide us 
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